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Abstract

THE ROLE OF SECRETED PHOSPHOPROTEIN-24 IN OSTEOBLAST
DIFFERENTIATION AND MATRIX MINERALIZATION
By Samuel C. Ramage, PhD.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2007
Major Director: Matthew J. Beckman, PhD.
Assistant Professor, Department of Biochemistry and Molecular Biology

Secreted Phosphoprotein-24 (Spp24) was initially isolated and characterized as a
component of bovine cortical bone matrix. Subsequent characterization has shown it is
multiply phosphorylated and homologous to cystatin and TGF-β receptor type II. Spp24 is
a minor component of the serum fetuin mineral complex that binds calcium-phosphate
minerals and prevents their deposition. The TGF-β receptor homology domain binds BMP2 weakly in vitro and enhances BMP-2’s osteogenic effects in vivo. The ability of Spp24 to

xi

xii
affect BMP activity suggests an important role for Spp24 as a native, bioactive component
of bone that regulates bone development.
Spp24 was highly up-regulated in rat cortical kidneys following a low calcium diet
regime. Tissue distribution of both Spp24 protein and RNA showed that while Spp24
accumulates in bone, a majority is produced at distant sites, namely the liver and kidney.
Additionally, Spp24 was present in more tissues than previously believed. Spp24 migrates
to a number of different molecular weights, suggesting multiple, alternative posttranslational modifications may generate subtly different forms of the protein. The
expression of Spp24 in the kidney may be regulated to counteract changes in serum
mineral levels. Additionally, homology in the Spp24 sequence suggests that it, like other
bone and dentine matrix proteins, may interact with mineral as an important influencer of
mineral calcification.
Utilizing microarray analysis of primary bone marrow-derived mesenchymal stem
cells transduced with Spp24 and control viruses we examined changes elicited by the
overexpression of Spp24. A change in overall morphology was observed for cells
transduced with the Spp24 similar to changes described in cells undergoing osteoblastic
differentiation. Nodule formation was also seen in the Spp24 transduced cells. Microarray
results showed key markers of osteoblast differentiation, CBFA1/RUNX2 and osterix
(OSX), were not up-regulated although there were distinguishable changes in the gene
expression profile of mesenchymal stem cells. The cells appeared to be blocked from
differentiation into a number of mesenchymal lineages: adipocytes, myocytes and
chondrocytes. The changes appeared to prime cells for signals that activate osteoblast

xiii
differentiation by blocking other pathways and altering internal signaling response
pathways to those signals.
This document was created in Microsoft Word 2003

Chapter One
General Introduction

Bone is an important organ with myriad functions in the body ranging from
mechanical support of the body to the protection of internal organs; it is also a critical
metabolic tissue used as a reservoir for vital minerals. Bone is a specialized extracellular
matrix laden with calcium phosphate crystals in the form of hydroxyapatite,
[Ca10(PO4)6(OH)2]. Bone is not a static mechanical support but rather is in a constant state
of flux with bone producing cells, called osteoblasts, and bone destroying cells, called
osteoclasts, in constant juxtaposition. Osteoblasts are responsible for the creation of the
complex extracellular matrix that provides the framework for cell attachment and mineral
deposition that enhances the mechanical strength of the bone while osteoclasts are uniquely
specialized to dissolve the mineral and then degrade the extracellular matrix of bone. The
continuous activity of these adversarial processes results in the turnover of the entire
skeleton roughly every 10 years (Parfitt 1998); the coupled processes of bone formation
and destruction are crucial to the strength of healthy bone and the repair of bone injuries
and fractures. Disruption of the delicate balance of these two opposing functions causing
1
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an excess of either formation or destruction can lead to serious pathophysiological
consequences.
Bone development is a highly synchronous process with a multitude of cytokines,
growth factors, and other signaling molecules carefully orchestrating the recruitment,
differentiation, development, and function of osteoblasts. Particularly important are wnt
family proteins and members of the transforming growth factor-β (TGF-β) family of
cytokines including bone morphogenetic proteins (BMPs). Similarly, a variety of signals
control osteoclastic bone resorption by regulating osteoclast differentiation and action.
This introduction will cover bone remodeling including the role of osteoblast and
osteoclasts; the basics of skeletal development; the differentiation of osteoblasts; and the
role of BMPs in osteoblast function. The focus will then shift to convey the current
understanding of Spp24 and its relation to several known bone matrix proteins.

Cellular Composition of Bone
Osteoblasts
Osteoblasts have specific molecular and morphological adaptations making them
particularly well suited for the task of producing the bone matrix. Osteoblasts are
mesenchymally derived cells that produce osteoid. They make prodigious amounts of
collagen type I, the principal bone ECM component. Smaller amounts of type III and V
collagen (Ashhurst 1990; Wood, Ashhurst et al. 1991) are present as part of the bone
matrix as well as bone sialoprotein and other non-collagenous matrix proteins. Several of
the FACIT (fibril associated collagens with interrupted triple helices) collagens, which are
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non-fibril/non-triple helical collagens that associate with fibril collagens, have been found
in bone and articular cartilage including collagen type IX, XII, and XIV (Walchli, Koch et
al. 1994; Dharmavaram, Huynh et al. 1998; Opolka, Ratzinger et al. 2007). Osteoblasts
have a large rough endoplasmic reticulum and Golgi apparatus (Baud 1968; Cameron
1968; Mandi, Gyarmati et al. 1974); the large volume of proteins that are produced and
eventually directed to the ECM requires this greater than normal amount of intracellular
machinery for the production and export of these proteins.
Terminally differentiated osteoblasts take on a cuboidal shape while the
proliferating osteoblast precursors maintain a more spindle-shaped morphology (Nijweide,
van der Plas et al. 1988; Cheng, Yang et al. 1994). Osteoblast in in vitro culture cluster
together forming closely associated nodules (Nefussi, Boy-Lefevre et al. 1985; Bhargava,
Bar-Lev et al. 1988). Osteoblasts are in close contact with each other in bone; N-cadherin
and cadherin-11 play a major role in forming the junctions between osteoblasts in addition
to several integrins (Cheng, Lecanda et al. 1998; Ferrari, Traianedes et al. 2000; Lecanda,
Cheng et al. 2000). Terminal differentiation is also marked by increased expression of
several mineral-interacting non-collagenous proteins such as osteopontin, osteocalcin, and
bone sialoprotein (Huq, Cross et al. 2005). Extracellular matrix vesicles are deposited by
osteoblasts, and chondrocytes, acting to accumulate sufficient concentrations of component
ions of hydroxyapatite crystals to aid in mineralization of the matrix (Anderson 1989;
Wiesmann, Meyer et al. 2005). It is thought that a number of constituents of the
extracellular matrix vesicles, such as phospholipids and mineral ions, can act to form a
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nucleation core for the growing crystal, aiding in the formation of the initial crystal – the
most energy consuming step in the process of mineral formation (Wuthier 1989).
An oft utilized characteristic of these cells is their production of alkaline
phosphatase. Many histological examinations of bone utilize staining to detect alkaline
phosphatase as a marker of osteoblasts in tissue or osteoblast character in differentiating
cells. Alkaline phosphatase’s role in mineralization was debated for some time with
different proposed roles for alkaline phosphatase such as degrading inhibitors of
mineralization; however the hypothesis of Robison that alkaline phosphatase creates a
local increase in inorganic phosphate concentration by hydrolyzing phosphate esters
(Robison 1923) appears to have been borne out.

Osteocytes
As the functional osteoblasts create bone matrix they are surrounded within their
own organic matrix; this matrix eventually becomes mineralized, trapping the osteoblast
inside the bone. These trapped osteoblasts extend long processes and decrease their size
and abundance of organelles as they become less metabolically active. Transformed
osteoblasts embedded within the bone interior are called osteocytes. Osteocytes are the
most numerous cells in the bone, largely occupying the interior volume of the bone while
most other cells such as osteoblasts and osteoclasts are present only on or near the bone
surface. Osteocytes produce far less extracellular matrix than the more active osteoblasts
(Nefussi, Sautier et al. 1991). Osteocytes are important regulators of bone metabolism and
communicators of mechanical stresses upon the bone. Osteocytes have a large number of
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long cellular projections that connect to other osteocytes through small tunnels in the bone.
The small tunnels, or cannaliculi, form an extensive network that allow interaction of
osteocytes and connect internal cells to the bone surface. Deformation of the osteocyte due
to strains on the bone and fluid flow through the cannaliculi have both been shown to act
through osteocytes to create changes in bone metabolism (Klein-Nulend, Helfrich et al.
1998; Plotkin, Mathov et al. 2005). A large number of different mechanisms have been
explored in the detection and communication of mechanical stress. Membrane ion channels
that are activated by the mechanical stress have been found in bone cells (McDonald and
Houston 1992; Ypey, Weidema et al. 1992; Rawlinson, Pitsillides et al. 1996). In addition,
integrins that act both as extracellular adhesion molecules and transmembrane receptors
(Hughes, Salter et al. 1993); the plasma membrane and its constituent proteins (Rubin,
Rubin et al. 2006); and cytoskeletal structures and their associated proteins all likely play a
role in the mechanotransduction in bone (Rubin, Rubin et al. 2006). One interesting
anabolic effect on bone in response to stress is the rapid upregulation of the canonical wnt
signaling in response to loading (Robinson, Chatterjee-Kishore et al. 2006; Armstrong,
Muzylak et al. 2007). Osteocytes, though not directly involved in the formation and
destruction at the bone surface, are critical components of healthy bones and the
maintenance of bone metabolism, and they sense and relay stresses to the cellular
components of bone.
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Osteoclasts
Mature, multi-nucleated osteoclasts are formed by the fusion of mono-nuclear
osteoclast precursors. Activation occurs as the non-resorbing or inactive osteoclast reaches
and adheres to the bone surface. Morphological changes allow the creation of a contained
compartment between the osteoclast and the bone called the resorption lacuna that is the
site of resorption. The degraded bone fragments are then removed and secreted away from
the bone surface. The specialized morphology of the osteoclast makes it extremely
efficient at absorbing bone.
Active osteoclasts are highly polarized cells with specific features characterizing
the surface adjacent to the bone. After recruitment, receptors on the plasma membrane
interact with the bone matrix to form the sealing zone, a tight interaction that creates a
sealed extracellular compartment between the osteoclast and bone. A portion of the cell
membrane, called the ruffled border, encircled by the sealing zone undergoes changes
resulting in significant endosomal character and finger-like projections of the membrane
towards the bone surface. Activation of the osteoclast triggers intracellular vesicles to fuse
with the membrane contained within the sealing zone. Fusion releases acid (H+) and other
vesicular contents into the resorption lacuna (Blair, Teitelbaum et al. 1989; Vaananen,
Karhukorpi et al. 1990). Fusion also increases the amount of membrane encompassed by
the sealing zone, leading to the
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development of the folds and extensions of the membrane into the resorption lacuna.
Within the ruffled border a high concentration of vacuolar ATPase were found (Vaananen,
Zhao et al. 2000). Osteoclasts use the many vacuolar ATPases to pump H+ into and further
acidify the resorption lacuna. Vesicle fusion and the activity of vacuolar ATPases are key
functions of the ruffled border that create an environment conducive to bone resorption
within the resorption lacuna. Degradation products from the organic bone matrix are
endocytosed by the osteoclast and trafficked to the apical region of the cell, called the
functional secretory domain, where they are secreted into the extracellular space.
Following osteoclast activation the resorption lacuna becomes highly acidic as
fusion of intracellular acidic vesicles with the ruffled border releases acid into the area of
active resorption and vacuolar ATPases pump protons across the membrane into the
resorption lacuna. The low pH achieved is necessary to dissolve the hydroxyapatite
crystals surrounding the organic matrix of the bone. Mineral crystals in bone must be
dissolved for the degradative enzymes secreted by the osteoclast to access the organic
matrix. Hydroxyapatite crystals in the bone store a majority of the calcium in the body, and
osteoclastic dissolution of the mineral component of bone is an important mechanism for
maintaining serum levels of calcium and other ions contained in bone such as phosphate.
Accordingly, the activity of osteoclasts is regulated in response to conditions such as
hypocalcemia to maintain suitable concentration ranges of those ions.
Following demineralization the osteoclast secretes enzymes that further degrade the
bone. The extracellular matrix made by osteoblasts and osteocytes is principally composed
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of collagen but contains other non-collagenous extracellular matrix proteins as well. The
matrix is principally degraded by two types of proteases, cathepsins and metalloproteinases
(MMPs). Cathepsins are lysosomal proteases active at acidic pH. Their activity at low pH
shows the importance of the osteoclast machinery responsible for lowering the pH of the
resorption lacuna in providing a suitably acidic environment for cathepsins and other acidic
proteases in addition to dissolving the hydroxyapatite. Osteoclasts produce cathepsin B, C,
D, E, G, L, and K (D and E are aspartatic proteases while the others are cysteine proteases)
(Goto, Yamaza et al. 2003). Cathepsin K, a lysosomal cysteine protease, has high
enzymatic activity towards type I collagen, the main component of bone, as well as type II
collagen (Bromme, Okamoto et al. 1996; Kafienah, Bromme et al. 1998). Cystatin C, a
secreted protein produced by osteoclasts, osteoblasts, as well as cells in the liver and
kidney (Yamaza, Tsuji et al. 2001), is an inhibitor of cysteine proteases. In vitro assays
have shown the addition of cystatin C decreases bone resorption (Lerner, Johansson et al.
1997).
MMPs are zinc-dependent proteases produced by a wide variety of cells in the
body. In bone osteoblasts, osteocytes, osteoclasts, and cells adjacent to and associated with
osteoclasts at the bone surface are all capable of producing MMPs. Many of the MMPs
present in bone show degradative activity against collagen. While most overlap in the
ability to degrade collagen and gelatin in some manner their specificity betrays their native
substrate. Several MMPs are made by osteoclasts including MMP-2, 9, 12, and 13. MMP13 is a collagenase capable of degrading triple helical collagen fibers. MMP-2 and -9 are
both gelatinases capable of degrading gelatin, byproducts of collagen hydrolysis. MMP-13
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is also known as macrophage metalloelastase as it has high specificity for hydrolyzing
elastin in addition to other ECM proteins. MMPs function in bone matrix degradation as
well as being important in allowing osteoclast migration. MMP-9 and -14 are critically
important, though distinctly so, in allowing osteoclast migration in bone (Delaisse,
Andersen et al. 2003). MMPs are regulated by tissue inhibitors of metalloproteinases
(TIMPs). Treating bone resorptive pathologies by targeting MMPs has proven an
important and successful pharmacological methodology. Although the administration of
bisphosphonates is used to inhibit and downregulate MMPs in bone resorption and other
diseases such as the metastases of cancer (Teronen, Heikkila et al. 1999), long term
consequences of these therapies are proving to be serious; numerous reviews detail these
effects including the greatly reducing bone turnover rate as well as the conferring a greater
risk of developing osteonecrosis of the jaw (Liberman 2006; Ponte Fernandez, Estefania
Fresco et al. 2006; Woo, Hellstein et al. 2006).
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Figure 1: Osteoclast Differentiation and Bone Resorption
Extensive research has showed that the accessory cells (osteoblasts and stromal cells)
express two key molecules that are essential and sufficient to promote osteoclastogenesis:
M-CSF and RANKL. Osteoclasts are multinucleated giant cells deriving from
hematopoietic progenitors of the monocyte–macrophage lineage. Stromal cell/osteoblast
cells express RANKL, OPG, and M-CSF and their expression is regulated by factors such
as 1,25(OH)2D3, PTH, PGE2, and glucocorticoids. RANKL and M-CSF will interact with
the cell surface receptors on mono/macrophage cells. These will trigger the
osteoclastogenesis process. These postmitotic committed precursors fuse to form
multinucleated osteoclasts, which are then activated to resorb bone. Osteoblasts or bone
marrow stromal cells are required as supporting cells for the in vitro differentiation of
osteoclasts from their progenitor cells. Source: Adapted from American Association for the
Advancement of Science (Teitelbaum 2000); Springer (Quinn, Neale et al. 1998); and
International and American Assciation for Dental Research (Reddy and Roodman 1998).
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Bone Remodeling
The extracellular matrix of bone is continually undergoing both resorption and
formation by cells of the bone. This activity, termed bone remodeling, is important in
maintaining the mechanical properties of bone necessary to support the weight of the entire
body and in releasing important minerals and growth factors embedded in the bone matrix.
Early in bone development, at embryonic and nascent stages, the bone matrix is a more
porous, disordered mat of collagen fibers known as woven bone (Weiner and Wagner
1998). As development progresses, bone remodeling removes and replaces the woven bone
with the mature lamellar bone that is easily identified by its parallel collagen fibers that
endow the bone with greater mechanical strength (Martin, Lau et al. 1996). Bone
remodeling is also critical in the maintenance of mineral homeostasis within the body.
Calcium and phosphate, the primary components of hydroxyapatite crystals, are liberated
from bone in response to signals that counteract dropping serum concentrations of these
minerals. Likewise, growth factors that have effects outside the bone can also be freed
from the bone matrix.
Bone continuously undergoes the process of bone remodeling where the both bone
formation and resorption are essential to the health of the bone. The loss of balance
between osteoblastic formation and osteoclastic degradation of bone is a key feature of
bone resorptive pathologies such as rheumatoid arthritis, osteopetrosis, osteoporosis,
periprosthetic osteolysis, and osteolytic malignant cancers among others (Nakashima,
Wada et al. 2003).
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Embryonic Skeletal Development
In the embryo, condensations of mesenchymal cells give rise to the mature skeletal
features. Cells from the neural crest, paraxial mesoderm, and the lateral plate mesoderm
are the ultimate sources of the mesenchymal cells that pattern skeletal development.
Mesenchymal precursor cells are pluripotent stem cells and the source of osteoblasts in the
skeleton. Mesenchymal stem cells (MSCs) have the capacity to become numerous types of
cells such as osteoblasts, chondrocytes, adipocytes, and myoblasts (Pittenger, Mackay et
al. 1999). The composition of the extracellular milieu of cytokines and growth factors
drives the differentiation of MSCs by signaling through pathways that eventually up- and
down-regulate a variety of transcription factors in a manner characteristic of the cells’
eventual fate.
Following MSC condensation there are two mechanisms for the creation of the
skeletal bones: membranous or endochondral ossification. Membranous ossification is the
process that begets many of the cranial and facial bones; MSCs differentiate into
osteoblasts and begin synthesizing bone matrix in the place of the prior mesenchymal
condensations. The differentiation of MSCs into osteoblasts occurs through the activity of
wnt family cytokines (Rawadi, Vayssiere et al. 2003). These extracellular ligands bind to
receptors on mesenchymal cells resulting in elevated β-catenin levels (Akiyama 2000) that
promote osteoblast differentiation (Bain, Muller et al. 2003; Westendorf, Kahler et al.
2004) and inhibit chondrocytic (Hill, Spater et al. 2005) and adipogenic (Kennell and
MacDougald 2005) differentiation. Endochondral ossification is a multi-step process in
which a cartilaginous matrix is produced by chondrocytes (in a low β-catenin environment)
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as a pre-cursor to the eventual bone. In a process requiring β-catenin, the chondrocytes will
cease to proliferate and transition to hypertrophy. The hypertrophic chondrocytes and their
matrix will eventually be replaced by osteoblasts and bone matrix.
During development, mesodermal cells form segmented structures on either side of
the dorsal midline of the embryo called somites. Cells in the somites will eventually
migrate nearer the dorsal midline and become the sclerotomes that gives rise to the spine
and ribs. Cell-cell interactions are particularly important in the patterning and transition of
cells that ultimately comprise the skeleton. Crucial to the patterning of cells in the somites
are interactions between the cell surface receptor notch, of which there are four types
Notch1 through Notch4, and the ligands for those receptors such as Delta-like ligands
including δ-like 3 (DLL3) and Jagged family ligands like Jagged-1 (Artavanis-Tsakonas,
Rand et al. 1999; Rida, Le Minh et al. 2004); significant skeletal defects are observed
when these interactions are disrupted (Li, Krantz et al. 1997; Oda, Elkahloun et al. 1997;
Saga, Hata et al. 1997; Wong, Zheng et al. 1997; Bulman, Kusumi et al. 2000). Notch
ligand proteins are single-pass transmembrane proteins and as such the notch/delta/jagged
signaling system is a two-cell paradigm requiring the presence of cells expressing the
ligand on their surface and cells expressing the receptor in order for signaling to occur.
Another protein, Sonic hedgehog, has been shown to also play a critical role in early
patterning that eventually yields skeletal development (Chiang, Litingtung et al. 1996).
This secreted protein produced in the adjacent notochord, another mesodermally derived
structure, regulates the differentiation of cells in the sclerotome.
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Figure 2. Notch Signaling
Notch signaling requires the presence of two cells; one with a notch ligand while the other
presents notch receptor so that the two molecules may interact in the extracellular space
with the receptor transducing the signal. Hedgehog signaling is also shown with the
transcription factor Gli acting as the effector of hedgehog signaling. Source: (Bailey, Singh
et al. 2007)
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Limb Development
Similar to embryonic bone development, the formation and growth of the adult
skeleton is under comparable regulation in the limbs. The long bones of the limbs, with the
exception of a subperiosteal layer of bone, are created through endochondral ossification.
Mesenchymal progenitor cells in the limb begin the differentiation to chondrocytes due to
the signaling of fibroblast growth factors, sonic hedgehog, TGF-β family cytokines and
others. As the development of the nascent limb progresses chondrocytes create a
cartilaginous model of the skeletal features. These cartilaginous pre-patterned skeletal
features, often called anlagen, lengthen the limb in the proximal to distal direction.
Sonic hedgehog and Indian hedgehog are also important regulators of the transition
of cells through stages of chondrocytic differentiation, increasing the proliferation of
chondrocytes and playing a role in regulating the rate of hypertrophic transition (Stott and
Chuong 1997; St-Jacques, Hammerschmidt et al. 1999). Indian Hedgehog (Ihh) also
enhances osteoblast differentiation during the process of endochondral bone formation
(Krishnan, Ma et al. 2001). Hedgehog signaling acts via the expression of PTH related
peptide (PTHrP). PTHrP limits chondrocyte differentiation to hypertrophy, and PTHrP
signaling through the PTHrP receptor has been shown to limit Indian hedgehog expression.
The interplay of hedgehog proteins and PTHrP generates an axis of signaling where Ihh
signaling maintains proliferative chondrocytes at the ends of bone while PTHrP blocks Ihh
expression allowing the transition to hypertrophy in more proximal portions of the limb
(Shum and Nuckolls 2002). The development of cartilage from mesenchymal
condensations occurs in areas of low β-catenin (Hill, Spater et al. 2005). The low β-catenin
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results in the up-regulation of SOX-9, a critical transcription factor for chondrogenic
differentiation (Akiyama, Lyons et al. 2004; Jin, Lee et al. 2006). This development
contrasts MSC differentiation to osteoblasts which requires the presence of extracellular
Wnt ligands that signal to increase β-catenin, leading to increased activity of osteoblastspecific transcription factors, among them core binding factor A1 (CBFA1/Runx2) and
osterix (Osx) (Kato, Patel et al. 2002).
As chondrocytes continue producing anlagen there is a change at the apical end that
transforms the chondrocytes. Chondrocytes at the leading edge continue to proliferate in
the developing bone while those behind the leading edge begin to differentiate into nonproliferative, hypertrophic chondrocytes. This process of appositional growth through the
formation of growth plates lengthens the forming bones. In the growth plates, proliferative
chondrocytes continue to divide resulting in bone lengthening. Behind the proliferative
chondrocytes the hypertrophic chondrocytes undergo subtle changes in preparation for the
beginning of bone formation. Eventually hypertrophic chondrocytes will die and be
replaced by osteoblasts as the bone lengthens. The matrix produced by the chondrocytes is
different from that of osteoblasts; there is even a great variance between the matrix made
by hypertrophic and proliferative chondrocytes. Proliferative chondrocytes produce a
collagenous matrix principally composed of type II collagen (Sandberg and Vuorio 1987).
Hypertrophic chondrocytes also produce type II collagen, however they are distinct in their
production of type X collagen and, as such, type X production is used as an indicator of
hypertrophic character (Hjelle and Gibson 1979; Schmid and Conrad 1982; Schmid and
Linsenmayer 1983; Capasso, Tajana et al. 1984; Solursh, Jensen et al. 1986; Bashey,
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Iannotti et al. 1991). As chondrocytes transition to hypertrophy they slow their
proliferation and also begin to express VEGF-A, an important angiogenic protein that
increases vascularization in preparation of osteoblast invasion and activity (Hall,
Westwood et al. 2006). The changes in the cartilaginous matrix of the hypertrophic region
create the necessary vasculature to allow osteogenesis to occur (Hall, Westwood et al.
2006). Mesenchymal cells recruited to the hypertrophic region that are exposed to Wnt
signaling and high vascularity begin the process of commitment to the osteoblast rather
than chondrocyte lineage and begin forming osteoid.
As endochondral ossification progresses more changes take place that lay the
groundwork for the subsequent osteoblast activity. FGF-18 is thought to play an important
role in dampening chondrocyte proliferation as well as initiating vascularization through
the up-regulation of VEGF and playing a role the transition to hypertrophy (Liu, Lavine et
al. 2007). Among the changes that occur during the differentiation of chondrocytes to the
hypertrophic stage is the increased expression of the transcription factor CBFA1/RUNX2
that results in a variety of changes including increased vascularization (Zelzer, Glotzer et
al. 2001). Vascularization is a necessary step to allow the pre-osteoblast cells to begin
invading the hypertrophic region (Zelzer, Mamluk et al. 2004). The osteoblasts begin to
finally lay down the bone matrix while proteases from chondrocytes and other cells act to
break down the cartilaginous matrix made in earlier stages of endochondral development
(Wu, Mwale et al. 2001; Chung 2004). Osteoblasts then proliferate from the center of the
bone to the ends following the proliferating and hypertrophic chondrocytes in sequence.
After the initial bone is formed, bone elongation occurs via the appositional growth
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through the epiphyseal growth plate with proliferative chondrocytes expanding the border
of growth plate and then transitioning to hypertrophic chondrocytes before dying.
Osteoblasts follow the hypertrophic chondrocytes and lengthen the bone through the
process of endochondral ossification as the growth plate moves distally.

Osteoblast Differentiation
Osteoblast differentiation is a key step in the generation of a normal, healthy
skeleton. Several steps and differentiating signals have been mentioned in previous
sections; however there is an abundance of other documented cytokines and growth factors
that influence osteoblast differentiation and activity. The extensive body of research on
osteoblastogenesis attests to its importance in skeletal development as does the number of
studies demonstrating both human and analogous pathologies in other species when there
is a disruption of the process.
In the differentiation of mesenchymal precursors to either osteoblasts or
chondroblasts canonical wnt signaling is the first major signaling point. Wnts are
extracellular ligands that show homology to the drosophila gene wg (wingless), and
vertebrate Int-1 genes; the combination of the two names yields “wnt” (Li, Chong et al.
2005). Wnt cytokines bind to their cognate extracellular receptors, members of the frizzled
family, and Lrp 5/6, a co-receptor, to transmit their signal to intracellular effectors (Bodine
and Komm 2006). Wnt signaling raises intracellular β-catenin levels by activating a protein
called disheveled (DSH) that blocks the proteasomal degradation of β-catenin in the cells
(Lee, Ishimoto et al. 1999; Seidensticker and Behrens 2000; Zhong, Gersch et al. 2006).
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Inhibition of proteasomal degradation allows the accumulation of β-catenin; elevated βcatenin levels in the cell are responsible for stimulating osteoblastic genes and inhibiting
chondrocytic genes (Day, Guo et al. 2005). Conversely, cells fated to become chondrocytes
are low in β-catenin allowing the up-regulation of transcription factors of the SOX family,
specifically SOX-9, that stimulate chondrocyte-specific genes (Hill, Spater et al. 2005;
Yano, Kugimiya et al. 2005). In cells along the pathway to osteoblasts, the elevated βcatenin levels lead to up-regulation of other transcription factors (Komori and Kishimoto
1998; Gaur, Lengner et al. 2005), chief among them being CBFA1/RUNX2, a critical
transcription factor in osteoblast development (Komori, Yagi et al. 1997; Otto, Thornell et
al. 1997; Komori and Kishimoto 1998). CBFA1 also up-regulates another transcriptionfactor OSX that is critical to osteoblast development (Nakashima, Zhou et al. 2002). Wnt
signaling has also been shown to regulate OSX expression in osteoblast differentiation of
mesenchymal progenitor cells (Day, Guo et al. 2005). CBFA1-null mice do not express
Osx while in Osx null mice no bone formation occurs showing that it is a transcription
factor acting downstream of CBFA1 in osteoblast differentiation (Nakashima, Zhou et al.
2002).
There is an alternate pathway of Wnt signaling called the non-canonical β-catenin
signaling pathway that utilizes the same frizzled receptor to bind and transduce Wnt
signaling however it acts independent of β-catenin levels and signaling. Alternately called
the Wnt/Calcium or Wnt/JNK pathways, these signaling mechanisms lead to an
intracellular release of calcium following Wnt binding to frizzled and result in activation of
calcium sensitive enzymes such as calcium-calmodulin dependent kinase II (CamKII) and
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protein kinase C (PKC) or calcineurin (CaCN)(Kuhl, Sheldahl et al. 2000; Sheldahl,
Slusarski et al. 2003). Wnt/Calcium signaling has been shown to affect Xenopus
development (Kinoshita, Iioka et al. 2003) as well as skeletal muscle formation in mice
(Steelman, Recknor et al. 2006).While not fully understood this alternate signaling
pathway for Wnts may be critically important in development and given the prevalence of
Wnt signals in bone its role in skeletal development needs further exploration.
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Figure 3. The Canonical Wnt Signaling Pathway
ß-Catenin exists in a cadherin-bound form that regulates adhesion; in a complex with axin,
APC, and GSK-3ß, where it is phosphorylated and targeted for degradation by ß-TrCP; or
in the nucleus. Wnt signaling, proceeding through Frizzled and Arrow–LRP-5/6, activates
Dishevelled (Dsh), which results in uncoupling ß-catenin from the degradation pathway
and its entry into the nucleus, where it acts to control transcription. The Wnt pathway is
also subject to extensive regulation and feedbackcontrol by extracellular factors that bind
Wnt [Wnt inhibitory factor (WIF) and Frizzled-related protein (FRP)] or the coreceptor
LRP (Dickkopf). Source: (Nelson and Nusse 2004)
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In addition to the key roles of wnt/canonical β-catenin signaling and the
characteristic osteoblast transcription factors CBFA1 and Osx, there are a variety of
growth factors and cytokines that affect osteoblast differentiation and activity. Perhaps the
most widely known group of bone anabolic factors is the bone morphogenetic protein
family or BMPs that will be discussed in detail in the following section. Among the many
other cytokines affecting osteoblast differentiation are insulin-like growth factors (IGFs),
epidermal growth factors (EGFs), hepatocyte growth factor (HGF), vitamin D, TGF-β,
parathyroid hormone (PTH), platelet derived growth factor (PDGF) and fibroblast growth
factors (FGFs). TGF-β cytokines have been shown to have dual effects; at early stage
osteoblast differentiation they can act to promote differentiation while they suppress
terminal differentiation of mesenchymal cells to osteoblasts (Moses and Serra 1996;
Janssens, ten Dijke et al. 2005). PDGF, IGFs, EGFs, and HGF have all been shown to
work to maintain osteoblast progenitors in proliferating stage and prevent terminal
differentiation (Stephan, Renjen et al. 2000; Rasubala, Yoshikawa et al. 2003). These are
important factors that increase osteoblast number as bone grows to keep pace with the
growing skeleton. Vitamin D, through its active metabolite 1α, 25-dihydroxyvitamin D3
(1,25(OH)2D3), has been shown to increase differentiation of osteoblast progenitors as seen
in increased alkaline phosphatase activity and osteocalcin expression (van Driel, Koedam
et al. 2006; van Driel, Koedam et al. 2006; Bosetti, Boccafoschi et al. 2007). Interestingly,
a recent experiment coupled both HGF and 1,25(OH)2D3 and saw an increase in osteoblast
number and characteristics including mineralization which was not seen with 1,25(OH)2D3
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treatment in the absence of HGF (D'Ippolito, Schiller et al. 2002). This illustrates the
complex interconnections of the cadre of cytokines acting to promote osteoblast
development in the skeleton and the synergistic manner in which they can act.
PTH is an important hormone in bone biology with diverse anabolic effects in bone
as well as regulation of osteoclast function. Consistent administration of PTH increases
osteoclast number and activity while intermittent administration has anabolic effects on
bone (Dobnig and Turner 1995; Schmidt, Dobnig et al. 1995; Lotinun, Sibonga et al.
2002). PTH related protein (PTHrP) is produced and acts locally, instead of being
produced in the parathyroid gland and acting systemically as does PTH. Both PTH and
PTHrP bind to and activate the PTH/PTHrP receptor (Lanske, Divieti et al. 1998).
FGFs play an important role in osteoblast biology by decreasing proliferation and
up-regulating osteoblast genes. FGF-2 promotes osteoblast differentiation and
responsiveness of mesenchymal cells in bone marrow to BMPs (Hurley, Tetradis et al.
1999; Montero, Okada et al. 2000; Marie, Debiais et al. 2002). FGF-2 can also activate
CBFA1 by phosphorylation in osteoblasts (Xiao, Jiang et al. 2002; Franceschi and Xiao
2003). A further effect of FGF-2 is to protect osteoblasts from apoptosis (Chaudhary and
Hruska 2001). FGF-18 is expressed in bone and cartilage and seems to play an important
role in the progression of limb development as mice lacking the gene for FGF-18 show
delayed ossification and increased chondrocytes at their joints (Ohbayashi, Shibayama et
al. 2002). Similarly, mutations of FGF receptors cause serious skeletal defects; mutations
in the gene for FGF receptor-3 (fgfr3) cause achondroplasia resulting in skeletal dwarfism
(Rousseau, Bonaventure et al. 1994; Shiang, Thompson et al. 1994; Ikegawa, Fukushima et
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al. 1995; Horton and Lunstrum 2002). There are a wide variety of other diseases that result
from mutations in any of the four FGF receptors (Ornitz 2005).
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Figure 4: Overview of Osteoblastogenesis
Figure 4 provides a pictorial overview of the process of osteoblastogenesis.
Osteoblastogenesis is the result of many different signals being received by stem cells that
ultimately result in the formation of new osteoblasts. As can be seen, osteogenic and
chondrogenic cells arise from very similar cells. Adapted from Trends in Cell Biology
(Hartmann 2006).
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Bone Morphogenetic Proteins
Marshall Urist described the isolation of non-collagenous proteins from decalcified
bone matrix and how their implantation into muscle induced ectopic bone formation (Urist
1965). This seminal discovery paved the way for the exploration of bone morphogenetic
proteins, their signaling mechanisms and effects. While the discovery of BMPs was a
watershed moment in orthopaedic discovery there were important studies that preceded
Urist’s. While using decalcified bone as a mechanism to deliver iodoform as an antiseptic
treatment for osteomyelitis, Senn discovered the ability of the decalcified bone matrix he
implanted to create new bone at the site of the osteomyelitic defect (Senn 1889; Senn
1889). Similar discoveries were made in subsequent decades using alcohol-extracted
(Levander 1934; Levander 1938) and EDTA-extracted (Ray and Holloway 1957; Sharrard
and Collins 1961) bone matrix showing bone formation in muscle tissue and juvenile
spinal fusion, respectively. These discoveries occurred over a long time period, with
publication dates ranging from 1889 for Senn (Senn 1889) to 1961 for Sharrard and
Collins (Sharrard and Collins 1961). Progress was initially slow in identifying the
component of bone matrix responsible as results were not easily reproducible and there
were technical hindrances to fully isolating and identifying the osteogenic component.
Additionally, there existed no functional assay to identify the transforming component
found in the bone matrix.
Marshall Urist’s discovery in 1965 of a substance he described as non-collagenous
proteins/bone morphogenetic proteins (NCP/BMPs) (Urist 1965) occurred while he was
investigating the mineralization of bone. His primary research and funding at the time was
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concerned with investigating the possibility of using strontium and tetracycline as therapies
in the treatment of osteogenic sarcoma; mineralization of bone was, at the time, a side
interest (Reddi 2003). Urist showed that demineralized bone matrices implanted in animals
as controls induced bone formation leading to the theory of autoinduction (Reddi 2003).
That discovery was the cornerstone in a brilliant career that saw Urist oversee the journal
Clinical Orthopaedics and Related Research for 27 years as editor as well as significant
research contributions in areas including: estrogen effects on bone, for which he won a
kappa delta award; the development of total hip replacements using metal components; and
bone induction.
Urist and others earnestly worked on isolating the bone inductive factor found in
the demineralized bone matrices. The work of Urist and other investigators eventually
resulted in the isolation and cloning of several BMPs, and in the decades since their initial
discovery, over thirty BMPs have been identified including a number in species other than
humans (Ducy and Karsenty 2000; Chen, Zhao et al. 2004). Many BMPs were cloned in
early stages of research in the field, including BMP-2 through BMP-7; however Urist’s
original BMP was never completely isolated to homogeneity. Several key characteristics of
Urist’s original substance were relayed in several papers (Urist, Chang et al. 1987; Urist,
Huo et al. 1987): An N-terminal sequence of 14 amino acids was obtained (Urist, Huo et
al. 1987); repeated attempts at more complete sequencing were hindered by a blocking of
the N-terminus (Urist, Huo et al. 1987); The protein was estimated to be 18.5 kDa;
reduction abrogated the osteoinductive effect of the substance (Urist, Chang et al. 1987);
limited proteolysis with pepsin or trypsin resulted in smaller fragments of the BMP with
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increased osteoinductive activity (Urist called the digested, more active form BMP-p for
BMP polypeptides) (Urist, Chang et al. 1987); and finally, Urist related in a personal
communication to collaborators that purification approaching homogeneity resulted in a
loss of osteogenic activity and that rescue of that activity was possible by combination
with other fractions (Behnam, Phillips et al. 2005). Despite all of the work and the great
many things that were known Urist’s BMP was never fully isolated, although Wozney, et
al. cloned a protein that co-eluted with other BMPs in their isolations that encoded a
structurally distinct protein from the other BMPs and named this protein BMP-1. Unlike
other BMPs which are TGF-β family cytokines, BMP-1 is a secreted metalloprotease that
contains a proteolytic domain, a protein-protein interaction domain, and an epidermal
growth factor-like domain (Bond and Beynon 1995; Zhang, Ge et al. 2006; Hopkins, Keles
et al. 2007). Despite the fact that the name BMP-1 suggests it is one in the same with
Urist’s original osteoinductive factor, Wozney’s isolation procedure differed significantly
in later steps and “distinguish it from any previously identified factor” (Wozney, Rosen et
al. 1988). Consequently, the identity of the protein component of non-collagenous bone
matrix that has the described characteristics that Urist assigned had yet to be identified.
BMPs are members of the TGF-β family of cytokines. The TGF-β family is
comprised of over forty known members linked structurally by the presence of a cysteine
knot found on one side of the protein (McDonald and Hendrickson 1993; Murray-Rust,
McDonald et al. 1993; Kingsley 1994; Griffith, Keck et al. 1996); among the known
family members are TGF-βs, BMPs, activins, nodal, and mullerian inhibiting substances.
BMPs, though named for their remarkable effects on bone generation, have been found to
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be important signaling molecules with multiple signaling funtions throughout the body.
BMPs play a particularly important role in spatial patterning of the developing embryo.
Based on their osteogenic properties, BMPs have been explored as potential
therapies for treating bone injuries and defects that require significant healing and
regeneration (Chen, Zhao et al. 2004). Currently two BMPs, BMP-2 and -7, are approved
for clinical use (De Biase and Capanna 2005), and multiple delivery mechanisms are being
studied. Gels, cements, and organic polymer matrices are all being studied to determine the
best mode of delivery for BMPs to induce bone regeneration (Geiger, Li et al. 2003; Hu,
Zhang et al. 2003; Seeherman and Wozney 2005). The retention of BMPs is a critical
aspect of their clinical efficacy (Uludag, Gao et al. 2001). There are several areas that have
been seen as problematic in utilizing BMPs for treating bone defects. First, the cost to use
a clinically effective dose is extremely high (Carlisle and Fischgrund 2005), and secondly,
diffusion away from the site of administration lowers the efficacy of the BMP treatment.
Additionally, there is some worry that BMP activity in tissue neighboring the application
site could induce calcification in unwanted areas (Carlisle and Fischgrund 2005). New
delivery devices for the use of BMPs in orthopaedic injuries will have to achieve the
necessary retention to be clinically effective.
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Table 1: Members of the BMP Family
The table provides the different members of the BMP family, the subfamilies they are
classified into, and some of their alternative names (Termaat, Den Boer et al. 2005).

35

BMP Subfamily

BMP Molecules

Synonym

BMP-2/4

BMP-2
BMP-4

BMP-2A
BMP-2B

BMP-3

BMP-3
BMP-3B

Osteogenin
GDF-10

BMP-7

BMP-5
BMP-6
BMP-7
BMP-8
BMP-8B

Vgr-1
OP-1
OP-2
OP-3

CDMP/GDF

BMP-12
BMP-13
BMP-14

CDMP-3 or GDF-7
CDMP-2 or GDF-6
CDMP-1 or GDF-5
GDF-2

Miscellaneous

BMP-9
BMP-10
BMP-11
BMP-15
BMP-16

GDF-11

GDF = growth differentiation factor; Vgr = vegetal-related; OP = osteogenic
protein; and CDMP = cartilage-derived morphogenetic protein.
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BMP Signaling
BMPs signal through type I and II serine-threonine kinase receptors spanning the
membrane of target cells. Signal transduction in these receptors has been most widely
studied for TGF-β receptors however it is thought to be very similar to BMP receptor
activity (Yamashita, Ten Dijke et al. 1996). BMP binding to the receptors leads to their
activation. Activated receptors are capable of turning on intracellular signaling cascades
involving Smad proteins; Smad proteins are named for their homology to the drosophila
family of proteins Mothers against decapentaplegic (Mad) and the C. elegans gene Sma.
Following translocation to the nucleus, Smads alter transcriptional activity of target genes.
There exist a number of regulatory checkpoints for BMP signaling with both extracellular
inhibitors of BMP signaling and intracellular modulators of BMP signal transduction
playing important roles in the process.
BMPs, a sub-family of TGF-β family cytokines, can be subdivided into several
distinct classes based upon their amino acid sequences and homology. BMP-2 and -4 are
members of one group; BMP-5 through -8 form a second group; also a group of BMP-3
and BMP-3b, also known as growth and differentiation factor-10 (GDF10) (Cunningham,
Jenkins et al. 1995). BMP-5, BMP-6, BMP-7 (OP-1) and BMP-8 (OP-2) are classified as
the A60 group because of their similarity to the Drosophila A60 protein (Kingsley 1994).
As referenced above, several BMPs have multiple names due to particular properties or
aspects of their discovery; a number of BMPs are alternately known as osteogenic proteins
(OP), cartilage derived morphogenetic proteins (CDMP), and growth and differentiation
factors (GDF). The synonyms of a number of known BMPs are listed in Table 1 BMP
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ligands activate their receptors as dimers (Kirsch, Sebald et al. 2000); crystallographic
studies have shown that BMP-2 homodimers are held together by a single intermolecular
disulfide bond and other non-covalent interactions (Scheufler, Sebald et al. 1999).
Dimerization is crucial to the formation of a ligand complex capable of eliciting signaling
from its cognate receptors. Formation of specific heterodimers, namely BMP-2/4 and
BMP-2/7, have been shown to be more efficacious in generating BMP signaling than
corresponding homodimers (Israel, Nove et al. 1996).
BMP ligands bind to type-I and type-II BMP receptors. There exist three type-I
BMP receptors: type-IA (BMPR-IA) also known as activin-like kinase receptor-3 [ALK3]); BMP receptor type-IB (BMPR-IB) or activin like kinase-6 (ALK-6); and binding has
also been shown to activin type-I receptors (ActR-I or ALK-2). Three type-II receptors that
bind BMPs have also been characterized: BMP receptor type-II (BMPR-II) and activin
type-II and -IIB receptors (ActR-II and ActR-IIB, respectively). Studies have shown the
binding of type I receptors to BMPs in the absence of type-II receptors shows significantly
lower affinity than when paired with type-II receptors (Koenig, Cook et al. 1994; ten
Dijke, Yamashita et al. 1994); likewise, the same was shown of BMP binding to type-II
receptors (Kawabata, Chytil et al. 1995; Nohno, Ishikawa et al. 1995; Rosenzweig,
Imamura et al. 1995). Each BMP ligand binds to one type-I and one type-II receptor, as a
result the dimeric ligand will bind to two of each of the receptors forming a
heterotetrameric receptor complex (Wrana, Attisano et al. 1992; Mathews and Vale 1993;
Yamashita, ten Dijke et al. 1994; Luo and Lodish 1996; Weis-Garcia and Massague 1996).
Multiple permutations of heteromeric receptor complexes can be formed from the various

38
type-I and type-II receptors, each with varying affinities for the different BMP ligands
(Yamashita, Ten Dijke et al. 1996).
The binding of a BMP ligand to the heteromeric receptor complex is the initial step
in the activation of BMP signaling. The binding of the ligand brings the type-I receptor in
such proximity to the type-II receptor that the constitutively active, intracellular kinase
domain of the type-II receptor can phosphorylate the type-I receptor (Wrana, Attisano et al.
1994; Attisano, Wrana et al. 1996). Phosphorylation of the type-I receptor activates its own
kinase domain which is responsible for the initiation of intracellular BMP signaling
(Wrana, Carcamo et al. 1992; Wieser, Attisano et al. 1993; Wrana, Attisano et al. 1994).
The type-I receptor’s kinase domain phosphorylates and activates Smad proteins that are
the effectors of BMP signaling inside the cell. There are three subsets of Smad proteins:
receptor regulated Smads (R-Smads), common mediator Smads (Co-Smads), and
inhibitory Smads (I-Smads). Smad1, Smad5, and Smad8 are R-Smads that are
phosphorylated by BMP type I receptors (Kretzschmar, Liu et al. 1997; Nishimura, Kato et
al. 1998; Kawai, Faucheu et al. 2000). Smad2 and Smad3 are also R-Smads, but they are
phosphorylated by TGF-β type-I receptors, not BMP receptors (Ferguson, Schwarz et al.
2000). The phosphorylated R-Smads then bind to Smad4, a Co-Smad (Kretzschmar, Liu et
al. 1997; Nishimura, Kato et al. 1998; Kawai, Faucheu et al. 2000). The Co-Smad/R-Smad
will migrate to the nucleus where they regulate transcriptional activity of target genes. ISmads, Smad6 and Smad7, disrupt this signaling in three ways: they can compete with RSmads for binding to activated type-I receptors (Hata, Lagna et al. 1998; Zhang, Fei et al.
2007), they can target type-I receptors for proteasomal degradation by the recruitment of
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ubiquitin ligases (Moren, Hellman et al. 2003; Moren, Imamura et al. 2005), and they can
act in the nucleus to inhibit transcription either as co-repressors (Bai, Shi et al. 2000) or via
the modification of histone acetylation states (Bai and Cao 2002).
In addition to I-Smads there are other intracellular modulators of BMP signaling
that act upon the Smad signaling cascade. Smad ubiquitin regulatory factors (Smurfs) are
E3 ubiquitin ligases that regulate the activity of numerous Smads. Smurfs, in their role as
HECT (homology to E6Ap carboxyl terminus) E3 ubiquitin ligases, can accept an
ubiquitin from an E2 conjugating enzyme and transfer it to a Smad protein (Ogunjimi,
Briant et al. 2005). The ubiquitination of the Smads can either target the Smad for
proteolytic degradation by the proteasome or in certain cases cytoplasmic retention
(preventing the nuclear translocation necessary for activated Smads to affect their signaling
function).
A recent report has delineated a novel mechanism regulating BMP signaling via
protein interaction with the cytoplasmic “tail” domain of the BMPRII; Tribbles-like
protein 3 (Trb3) is a BMPRII “tail” domain-interacting protein that dissociates upon BMP
ligand binding (Chan, Nguyen et al. 2007). The release of Trb3 causes the degradation of
Smurf1, resulting in increased stability of R-Smads and increased BMP signal transduction
through Smads. Conversely, downregulation of Trb3 leads to increased Smurf1 levels and
greater repression of BMP signaling.
In addition to the intracellular regulation, a number of other molecules act to
modulate BMP signaling extracellularly. Several proteins are found in the extracellular
space that inhibit BMP signaling by binding to BMP ligands preventing their interaction
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with receptors found on the cell surface. Follistatin, follistatin-related protein (FSRP),
noggin, chordin, DAN/Cerberus family proteins, Decorin, Gremlin, Lefty, LTBP1,
THBS1, and sclerostin (SOST) are all among the proteins currently identified to inhibit
BMP binding in this manner. Bone morphogenetic protein-binding endothelial cell
precursor-derived regulator (BMPER) also plays a key role in patterning through the
regulation of BMP-4 signaling in embryonic patterning (Moser, Binder et al. 2003), likely
through the presence of cysteine-rich (CR) von Willebrand C-like domains as has been
shown for Chordin (Larrain, Bachiller et al. 2000). This protein is also a secreted BMP
antagonist shown to bind BMP-2, -4, and -6, affecting the BMP-4 driven differentiation of
endothelial cells in the embryo. These proteins play many roles in regulating BMP
signaling, but principal among those may be the ability to inhibit BMP signaling and create
gradients of BMP action which are crucial in establishing the patterning of the developing
embryo. The differing affinities and focalized expression allows the generation of gradients
for different BMPs in numerous spatial regions. The crucial role for these proteins in
embryonic development is seen in both the abnormally patterned and deformed animals
and the numerous inviable embryos when knockout animals for these BMP antagonists are
created, as reviewed by Balemans and van Hul (Balemans and Van Hul 2002).
A fairly recent addition to the known regulators of TGF-β cytokine signaling is the
pseudoreceptor BMP and activin membrane bound inhibitor (BAMBI) identified in
Xenopus and its mammalian homologue Nma. BAMBI is highly similar to the type-I serine
threonine kinase receptors except it lacks the intracellular signaling domain (Onichtchouk,
Chen et al. 1999; Grotewold, Plum et al. 2001). The stable association of BAMBI with
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other serine threonine receptors prevents the initiation of signaling once ligand binding
occurs (Onichtchouk, Chen et al. 1999). In Xenopus, frogs, and mice BAMBI was
expressed with BMP-4 during embryonic development, but despite the findings in these
model organisms the role of this antagonist of TGF-β signaling is not fully understood
(Onichtchouk, Chen et al. 1999; Grotewold, Plum et al. 2001; Knight, Simmons et al.
2001).
Another family of proteins that regulates the intracellular signaling of TGF-β
family cytokines by affecting the cellular localization of R-Smads has been identified. Zinc
finger FYVE domain-containing protein-9, also known as Smad anchor for receptor
activation (SARA), is a membrane bound anchor that binds to R-Smads (Smads 2 and 3) as
well as TGF-β receptor type I (Tsukazaki, Chiang et al. 1998). SARA also is suggested to
play an additional role in enhancing multiple phosphorylation of Smads by binding to
monophosphorylated Smads and retaining them to increase the likelihood of multiple
phosphorylation (Ottesen, Huse et al. 2004). An analogous protein to zinc finger FYVE
domain-containing protein-9 for TGF-β signaling, called endorphin for its endosomal
localization, has been identified for BMP signaling that acts on Smad-4 (Seet and Hong
2001; Chen, Wang et al. 2007; Shi, Chang et al. 2007). These families of proteins appear to
play important roles in the facilitation of R-Smad phosphorylation however the ultimate
purpose of the regulation is not fully established.
While the other aforementioned regulators of BMP and TGF-β signaling are
antagonists there are reports in the literature of potentiators of BMP signaling. DRAGON,
a glycosylphosphatydilinositol (GPI)-anchored membrane bound protein, has been shown
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to specifically enhance the signaling of certain BMPs while not showing the same effect
for TGF-β ligands. DRAGON (RGMb) is a member of the repulsive guidance molecule
(RGM) family. DRAGON binds to BMP-2 and -4 but not BMP-7. It also binds to type-I
and type-II BMP receptors and enhances BMP signaling. Recently, hemojuvelin, another
repulsive guidance molecule (RGM) family member was also found to mediate BMP
signaling as a co-receptor (Babitt, Huang et al. 2006). Hemojuvelin plays a specialized role
in regulating cellular uptake of iron in the liver (Papanikolaou, Samuels et al. 2004;
Niederkofler, Salie et al. 2005).
Interestingly, another GPI-anchored protein, Cripto, enhances TGF-β ligand
binding to activin receptors while blocking activin binding (Yan, Liu et al. 2002; Gray,
Shani et al. 2006). Cripto can act either as a soluble or membrane bound receptor/coreceptor depending upon the species examined (Rosa 2002). Cripto binds to nodal (another
class of TGF-β ligand) and to activin-like kinase-4 (ALK4) which is a TGF-β type I
receptor (Yeo and Whitman 2001). Cripto can also potentiate the signaling of nodal
through ALK7 (Reissmann, Jornvall et al. 2001). Cripto appears to possess an ability to
modulate the differential use of these receptors as their native affinities vary greatly; in the
absence of cripto ALK4 has a high affinity for and robust activation by nodal whereas
ALK7 is only weakly activated (Rosa 2002). Cripto also binds to activins in concert with
Activin type II receptors to block signaling (Gray, Harrison et al. 2003), an opposing
function to that seen in the binding of cripto to nodal ligands.
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Figure 5. TGF-β Family Cytokine Signaling
TGF-β family signaling can be grouped by the three types of ligands: activins/nodal, TGFβ, and BMPs. The figure depicts these signaling ligands and their cognate receptors and
their Smad signaling partners.
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Figure 6. The BMP Signaling Pathway.
Figure 6 shows the BMP signaling pathway, from the cell membrane to the nucleus. In
mammals, the R-Smads are Smads-1, -5, and -8, and the lone Co-Smad is Smad-4.
Though they are not shown in figure 6, there are two inhibitory Smads (I-Smads), also
called Smads-6 and -7. Source: (Balemans and Van Hul 2002))
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Secreted Phosphoprotein-24
Secreted Phosphoprotein-24 (Spp24) was initially isolated as a non-collagenous
bovine bone matrix protein (Hu, Coulson et al. 1995) in an attempt to isolate and
characterize potentially novel, bioactive bone matrix proteins. Although this was the first
characterization to purity there are reports in the literature of isolations of bone matrix
proteins with strikingly similar characteristics to those described for Spp24. Sen, et al.
described their “primary osteogenic factor” as a 23 kDa protein isolated from bovine bone
(Sen, Walker et al. 1987). Their intent was to isolate large amounts of homogenous bone
matrix proteins. They looked within the range of 10 to 30 kDa as Urist’s (Urist 1965; Urist,
Huo et al. 1984; Urist, Chang et al. 1987; Urist, Huo et al. 1987) and Reddi’s (Sampath,
DeSimone et al. 1982) groups had noted the presence of an osteogenic molecule in this
range. Reddi and collaborators also showed the presence of a 22 kDa protein that they
believed possessed the ability to induce mitogenic activity in mesenchymal cells similar to
that observed in the early stages of ossification-inducing experiments that implant
demineralized bone matrix (Sampath, DeSimone et al. 1982). Reddi’s report suggests there
may be a closely associated factor in bone matrix that controls mesenchymal cell
proliferation and differentiation but it is limited in providing identifiable characteristics of
the factor. Sen, et al., in seeking to establish a protocol that would provide adequate
amounts of bone matrix isolated BMPs, found their “primary osteogenic protein” (Sen,
Walker et al. 1987). The sequencing of a small portion of this protein is nearly identical to
the N-terminal sequence of bovine Spp24 (Figure 7) while the overall amino acid
composition was highly similar to the composition of Spp24, suggesting that the primary
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osteogenic factor and Spp24 are one and the same. Their isolation of Spp24 yielded a 23
kDa protein that they found, upon implantation into animals to induce bone formation.
Despite these early works that appear to have found Spp24 is a bioactive molecule, little
research was performed subsequently to elaborate on these discoveries and until quite
recently there was still little known about Spp24.
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Figure 7: Sequence Comparison of Sen, et al.’s Primary Osteogenic Factor with the
Bovine Spp24 Sequence
The N-terminal sequence (upper sequence) reported by Sen et al in 19?? of their
“primary osteogenic factor” isolated via a protocol that was based on the work of Urist and
modified slightly. They reported significant osteogenic properties of this protein. Sen et al
also report the primary osteogenic factor as a 23kDa protein. The sequence of the Nterminal portion of Spp24 is shown (lower sequence) for comparison to illustrate that Sen’s
primary osteogenic factor was most likely Spp24.
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Hu, et al. found that Spp24 was a 24 kDa protein that was phosphorylated on
multiple serines that conformed to the recognition motif for secretory pathway protein
kinase (Meggio, Boulton et al. 1988). Additionally, Hu, et al. showed Spp24 contains a
cystatin homology domain near its N-terminus. Spp24 was seen in a Northern blot of a
variety of bovine tissues to be expressed in the bone periosteum and to a greater extent in
the liver (Hu, Coulson et al. 1995). Expression of Spp24 in the liver was also seen in
microarray of hepatocarcinoma cells (Tackels-Horne, Goodman et al. 2001). While Hu, et
al. did not see expression in the kidney in their bovine tissues, microarray of genes
regulated in response to salt-sensitive hypertension did show expression of an expressed
sequence tag (EST) similar to Spp24 in the renal medulla of the kidney (Liang, Yuan et al.
2002).
Isolation and analysis of the fetuin mineral complex (FMC) in Etidronate treated
rats showed that Spp24 was a minor fraction of the complex (Price, Nguyen et al. 2003).
The FMC is a serum protein-mineral complex that acts to prevent the precipitation and
growth of mineral in bone (Price, Caputo et al. 2002; Price and Lim 2003). The FMC was
shown to be primarily composed of fetuin and minor amounts of matrix Gla protein,
Spp24, serum amyloid P component, and prothrombin (Price, Nguyen et al. 2003). The
complex is thought to form as local concentrations of calcium rise and
nucleation of mineral crystals occurs; soluble fetuin then forms the complex with these
mineral crystals arresting their growth (Price, Nguyen et al. 2003).
A detailed analysis of the sequence of Spp24 in nine species showed the presence
of several critical conserved features that added to the understanding of Spp24’s function

52
(Bennett, Khorram Khorshid et al. 2004). The gene encoding Spp24 (SPP2) is comprised
of eight exons with the first seven containing the coding sequence for the peptide and the
final exon containing the 3’ untranslated region of the messenger RNA (Bennett, Khorram
Khorshid et al. 2004). The organization of the gene, with the stop codon present in the
penultimate exon, is rare and highly indicative of secreted proteins (Nagy and Maquat
1998; Bennett, Khorram Khorshid et al. 2004). The human sequence of Spp24 contains a
29 amino acid signal peptide allowing secretion of the mature peptide to the extracellular
space. The N-terminal portion of the mature peptide was shown to have a cystatin
homology domain. Two such regions can be found in the protein fetuin (Demetriou,
Binkert et al. 1996). Cystatins are a family of cysteine protease inhibitors (Brzin, Popovic
et al. 1984; Goto, Yamaza et al. 2003). Proteins with cystatin homology have been shown
to possess the ability to inhibit cysteine protease activity (Lerner, Johansson et al. 1997).
This can greatly affect bone degradation by limiting cathepsins, cysteine proteases
involved in proteolytic break down of bone. At the C-terminal end of the cystatin domains
lies a TGF-β-receptor II homology domain. As mentioned previously the C-terminal
portion of the mature peptide contains a number of phosphorylated serines.
Spp24 was localized to the 2q37 chromosome by in situ hybridization (Swallow,
Merrison et al. 1997). Interestingly, some deletions in this region have been shown to be
related to the Albright hereditary osteodystrophy-like (AHO-like) syndrome. AHO-like
syndrome symptoms include brachydactyly and craniofacial defects (Chassaing, De Mas et
al. 2004; Shrimpton, Braddock et al. 2004; Chaabouni, Le Merrer et al. 2006). While most
cases are related to lowered levels of Gs alpha protein signaling, there are reports of cases
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with cryptic deletions where normal activity of the Gs alpha persists (Chassaing, De Mas et
al. 2004). If this deletion is related to Spp24, it would suggest the importance of Spp24 in
bone development and morphology.
The early work on Spp24 has shown a striking similarity of several aspects of
Spp24 biology with the protein fetuin. Fetuin and its human homolog, α2-HS glycoprotein,
are serum glycoproteins that, like Spp24, accumulate in bone (Yang, Chen et al. 1992;
Demetriou, Binkert et al. 1996; Binkert, Demetriou et al. 1999; Price and Lim 2003; Price,
Nguyen et al. 2003). Fetuin has been shown to have two cystatin domains similar to the
one present in Spp24, and like Spp24 there is a TGF-β receptor homology domain in the
second cystatin domain of fetuin (Demetriou, Binkert et al. 1996). In vitro assays have
shown the ability of the full length fetuin to bind to TGF-β family members including
BMPs (Demetriou, Binkert et al. 1996). Fetuin is the primary component of the fetuin
mineral complex, described earlier to play a role in preventing mineral deposition by
binding calcium (Schinke, Amendt et al. 1996; Schafer, Heiss et al. 2003).

54

Figure 8: Schematic Depiction of the Domains Found in Spp24
The signal peptide at the N-terminal end of the peptide is essential for the proper secretion
of the protein product and is cleaved upon secretion. The mature peptide, after signal
peptide cleavage, has a cystatin homology domain at its N-terminus. Contained with in the
cystatin domain is the TGFβ receptor type II homology domain. The C-terminal portion of
the protein is a Spp24 signature domain conserved in Spp24 across numerous species,
mostly vertebrates. Within the Spp24 signature domain are numerous phosphorylated
residues; Hu, et al. (Hu, Coulson et al. 1995) found that numerous serines were
phosphorylated and were found in sequences conforming to the secretory pathway protein
kinase. Additionally there serines in a SSEE sequence that is a recognition sequence for
casein kinase II and in SIBLING family proteins is important in hydroxyapatite binding
(Veis, Sfeir et al. 1997; Huq, Cross et al. 2005).
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Additionally, a blast search using the amino acid sequence of Spp24 revealed that
there is also homology to cathelicidin. Cathelicidins are members of a group of antimicrobial peptides expressed in a large number of tissues such as skin, vaginal mucosa,
airway, bone marrow and the digestive tract. Additionally, cathelicidins have been shown
to play a role in the response to viral infection and to modulate immune and inflammatory
responses (Bals and Wilson 2003; Braff, Hawkins et al. 2005; Gordon, Huang et al. 2005;
Durr, Sudheendra et al. 2006). At present the relation of Spp24, a bone matrix protein also
found at low levels circulating in serum as part of the FMC, to an antimicrobial peptide is
unclear. Homology between antimicrobial peptides, namely bactenectin and cathelicidin,
and cystatins and cystatin homologous proteins has been documented previously.
Cathelicidins conatin two domains: the N-terminal prosequence (sometimes called
“cathelin-like”) and the C-terminal antimicrobial domain (in the lone human cathelicidin,
hCAP18/LL-37, this domain is called LL-37). The N-terminal cathelin-like fragment that
is proteolytically cleaved to liberate the LL-37 domain has been shown to have antimicrobial activity (Zaiou, Nizet et al. 2003). This domain also is similar to cystatins and
can inhibit cysteine proteases (Zaiou, Nizet et al. 2003). Spp24 is more closely related to
cystatin and kininogen (which also contains a cystatin homology domain) than to
antimicrobial peptides. Due to its relation to both cystatins and antimicrobial peptides Hu,
et al. have suggested that Spp24 may be an evolutionary bridge between these cystatins
and antimicrobial peptides (Hu, Coulson et al. 1995). It is unclear what effect this may
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have in bone biology and whether there is a functional antimicrobial effect seen with
Spp24 that matches with the sequence homology observed.
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Figure 9. Structural Similarity of Spp24 and Cathelicidin-like Peptide
Ribbon structures show the similarities between Spp24 and Cathelicidin-like peptide. The
anti-paralell β-sheets and the α-helix are positioned similarly in both molecules as are the
loop connecting the two (green).
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In 2005, Behnam, et al., based on Urist’s original isolation procedure, were able to
isolate an 18.5 kDa protein that upon analysis was revealed to be a fragment of Spp24
(Behnam, Phillips et al. 2005). This fragment was similar to the protein fetuin, containing a
cystatin homology domain. In addition, the 18.5 kDa peptide had a TGF-β-receptor II
homology region. Behnam, et al. then made a synthetic peptide containing the region
suspected of being responsible for the BMP-like properties, a 19 amino acid region
containing the TGF-β-receptor homology domain. The synthetic peptide, which they called
BMP binding peptide (BBP), contained cysteines at either end that, based on comparison
with fetuin, were likely responsible for a disulfide bond and were used to create a cyclic
BBP. Implantation of BBP into muscle pouches of mice induced ectopic calcification.
When BMP-2 was implanted alone or with the BBP there was greater calcification seen
with the combination of BBP and BMP-2 showing the ability of BBP to enhance BMP
activity. Based on the activity of the BBP, Spp24 appears to enhance BMP signaling
through its TGF-β-receptor homology domain.
Spp24 has also been identified as a shown to be highly up-regulated in articular
cartilage in a model of osteoarthritis. This limited study did not elaborate on any role of
Spp24 either as causative or counteractive to the progression of the osteoarthritis. The
proposed biology of Spp24 to act to modulate BMP signaling through binding of TGF-β
ligands to the TGF-β receptor II homology domain could be an important factor as TGF-βs
play an important role in chondrocyte biology in addition to BMPs.
Recent work by Dalgleish and his collaborators (personal communication) has
found the sequence of the Spp24 gene in 22 vertebrate species including the cartilaginous
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dogfish. A number of aspects of the sequence were found to be conserved throughout all
species implying that these conserved amino acids may be critical to the native function of
Spp24. Two pairs of cysteines were found to be conserved throughout all species and these
were shown by Bennett, et al. to be involved in disulfide bridges, with the second pair
involved in the formation of the disulfide bridge flanking the TGF-β receptor II homology
domain structure (Demetriou, Binkert et al. 1996; Bennett, Khorram Khorshid et al. 2004).
A number of serines were additionally shown to be highly conserved. Some of the
conserved serines were shown by Hu, et al. to be phosphorylated and correspond to the
recognition motif of SXE/S(P)-specific secretory pathway kinase (Hu, Coulson et al.
1995). While Hu, et al. have shown that a number of serines were phosphorylated, it is
unclear whether all of the conserved serines and threonines are modified in this manner
(Hu, Coulson et al. 1995). Also unknown is the function of an Asparagine conserved
through all 21 species examined (N52 in the human sequence).
Another conserved aspect of the sequences was the presence of a four amino acid
stretch of SSEE. This sequence is recognized by the casein kinase-II and highly indicative
of a class of proteins called the SIBLING family of proteins. SIBLING proteins are a
family of ECM proteins found to associate with hydroxyapatite crystals. These proteins are
primarily found in bone and dentine ECM. SIBLING family proteins often contain a
consensus sequence (SSEE) for phosphorylation by casein kinase II (Veis, Sfeir et al.
1997; Huq, Cross et al. 2005). The presence of Spp24 within the bone matrix and the
association of Spp24 with mineral crystals as a portion of the fetuin mineral complex may
suggest that in bone Spp24 acts similar to SIBLING proteins as a stabilizer of

62
hydroxyapatite interaction with the bone matrix (Huq, Cross et al. 2005). SIBLING
proteins undergo numerous post-translational modifications. Though made as a full-length
proteins they are often found in the extracellular space as proteolytically cleaved forms
(Qin, Baba et al. 2004). The enzyme PHEX (Qin, Baba et al. 2004) and several MMPs
(Ogbureke and Fisher 2004; Ogbureke and Fisher 2005) have been shown to be coexpressed with SIBLINGS. As Behnam, et al. have identified a bioactive fragment of
Spp24 that is ~18.5 kDa (Behnam, Phillips et al. 2005) the relation to SIBLING proteins
and their proteolytic activation may be noteworthy similarity that could provide clues to
how Spp24 is cleaved to generate the bioactive form Interestingly, in the sequence
comparison performed by collaborators (Dalgleish and co-workers) the SSEE sequence
was conserved even in the cartilaginous dogfish (figure 10). The presence of this feature in
a cartilaginous fish would seem to belay the role of the SSEE consensus sequence in
calcification, but upon closer examination it may still play the same vital role in the
dogfish. The dogfish, though called a cartilaginous fish, still contains mineralized skeletal
features. The dogfish contains a cartilaginous skeleton that is produced by chondrocytes,
however a portion of the skeleton is mineralized with three distinct types of mineral
formed depending on the matrix features (Dean and Summers 2006). Also there exist, in
the vertebrae, areas that contain a mineralized “bone” that contains osteoblasts, osteocytes
as well as a matrix comprised primarily of type-I collagen (Peignoux-Deville, Lallier et al.
1982). The presence of mineralized cartilage and bone suggests that the SSEE domain
could be an important feature of Spp24 that enhances calcification in the extracellular
matrix even in the primitive skeleton of the dogfish.
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Figure 10. Alignment of Spp24 sequences from 22 Species
Alignment of Spp24 amino acid sequences from 22 species of vertebrates including the
cartilaginous dogfish. The degree to which residues are conserved across species is
indicated by the bar graph below each position. Residues conserved throughout are
denoted with an asterisk (*). Residues with similar amino acids are noted by one (·)
(moderately conserved) or two dots (:)(highly conserved) and Source: Dalgleish
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CHAPTER 2
Characterization of Secreted Phosphoprotein-24 Expression: Relation to
Kidney and Bone Cell Models

Abstract
Secreted phosphoprotein-24 (Spp24) is a non-collagenous bone extracellular matrix
molecule comprised of a cystatin-like domain at its N-terminal end and a signature Spp24
homology domain found only in vertebrate species. Spp24 has previously been
demonstrated to associate with the serum fetuin mineral complex and localize to bone as a
24 kDa protein. It also has been demonstrated to play a role in facilitating the ectopic bone
forming action of bone morphogenetic protein-2. The purpose of this study was to examine
Spp24 gene expression and protein localization in multiple tissues, particularly in the rat.
Assessment of the tissue distribution of Spp24 gene expression in rat showed transcript
detection in only the liver and kidney tissues. Spp24 was found to be expressed in kidney
tissue of rats at a level of one third the expression in liver. The protein form of Spp24 also
was studied in multiple human tissues and human/mouse kidney and bone cells and
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discovered to be ubiquitous and migrate at multiple molecular weight sizes, indicating
extensive potential for post-translational processing. Applying the techniques of
differential display RT-PCR and GeneChip microarray to rat kidney cortical RNA samples
from in vivo models of hypo- and hypercalcemia, we identified the differential upregulation of Spp24 in the hypocalcemic model. Renal Spp24 mRNA up-regulation in the
low calcium condition was confirmed by Real-Time Q-PCR as being 2.5 fold up-regulated
in hypocalcemic kidneys compared to its gene expression in kidneys obtained from normal
diet fed control rats. Detailed analysis of Spp24 mRNA and protein in histological sections
of rat kidney revealed that Spp24 is expressed in the epithelial cell layer of convoluted
tubules in kidney cortex. In conclusion, Spp24 predominantly originates from source tissue
outside of bone including kidney. Also the tissue distribution is more widely spread than
previously appreciated, indicating that Spp24 could regulate renal and extrarenal functions
as well as those presently assigned to bone.

Introduction
Skeletal development is characterized by a continuous turnover of the bone
extracellular matrix (ECM) and mineral components. In this process there is first an
increase in resorption by osteoclasts followed by reactive bone formation mediated by the
recruitment of osteoblasts derived from mesenchymal stem cell progenitors. In the adult
skeleton the bone remodeling process occurs simultaneously at millions of discrete foci
called bone remodeling units. The process ensures the mechanical integrity of the skeleton
throughout life and plays an important role in calcium homeostasis. Factors that disrupt the

67
intimate balance between bone resorption and bone formation result in offsetting metabolic
pathologies such as osteoporosis.
Secreted phosphoprotein 24 (Spp24), so named for its 24 kDa size in bovine
cortical bone, was isolated from partially purified bovine cortical bone. The sequence of
the isolated Spp24 was 200 residues; the first 20 residues contained the signal peptide with
the remaining 180-residues being translated into the mature Spp24 protein (Hu, Coulson et
al. 1995). The gene encoding Spp24 was later assigned to the human chromosome band
2q37 by fluorescence in situ hybridization (Swallow, Merrison et al. 1997). The 24 kDa
protein resulting from the Spp24 gene contains an N-terminal sequence of 107 amino acid
residues similar in sequence to cystatin; this similarity gives Spp24 structural and possibly
functional similarity to bone related cystatins (Brage, Lie et al. 2004; Brage, Abrahamson
et al. 2005; Danjo, Yamaza et al. 2007). Sequences related to cystatin are thiol protease
inhibitors. Given that Spp24 is found in bone, it could function to modulate the thiol
protease activities known to be involved in bone turnover. The cystatin homology region in
Spp24 overlaps a transforming growth factor-β-receptor II (TβRII) homology domain that
was suggested by Benham, et al. to affect BMP signaling in bone based on its ability to
bind bone morphogenetic proteins (BMPs) and other transforming growth factor-β (TGFβ) superfamily cytokines (Behnam, Phillips et al. 2005). The C-terminal half of the protein
also contains several phosphorylated serines (Hu, Coulson et al. 1995). Within Spp24 there
is a region of approximately 140 amino acid residues that represents the Spp24 homology
domain that is conserved in vertebrates.
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Spp24 was also found to be a minor fraction of the fetuin-mineral complex, a serum
complex important in inhibiting mineralization and comprised primarily of fetuin, 46% by
mass (Price, Nguyen et al. 2003). The fetuin-mineral complex has been shown to
participate in resisting bone mineral crystallization and may be important in maintaining
homeostasis with respect to mineralization (Price, Caputo et al. 2002; Price and Lim 2003).
Other proteins such as matrix Gla protein (MGP) were found in smaller proportions (Price,
Nguyen et al. 2003), and the remainder of the complex is composed of calcium-phosphate
minerals. The fetuin-mineral complex is proposed to bind calcium via acidic residues of its
constituent proteins, preventing the precipitation of calcium-phosphate ions liberated by
osteoclasts during bone resorption. Disruption of normal fetuin mineral complex function,
either by blocking acidic residues or by targeted mutations of individual components of the
complex such as MGP or fetuin, result in decreased management of extraskeletal
calcification (Schinke, Amendt et al. 1996; Jahnen-Dechent, Schinke et al. 1997; Munroe,
Olgunturk et al. 1999).
Like Spp24, both Fetuin and MGP accumulate in bone and contain several
phosphoserine residues potentially important to their function in bone (Price, Nguyen et al.
2003). Spp24 and fetuin also share cystatin homology domains in their N-terminal protein
sequences (Hu, Coulson et al. 1995) categorizing them both among the cystatin superfamily of cysteine protease inhibitors. The phosphorylation sites of MGP and fetuin are
present near their respective C-termini. Similarly, the bovine Spp24 was also found to be
multiply phosphorylated at serine residues that conform to the Ser-X-Glu/Ser(P) sequence,
a recognition motif for phosphorylation by the secretory pathway protein kinase (Meggio,
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Boulton et al. 1988). Spp24 also contains the conserved sequence for casein kinase II
phosphorylation (SSEE) (Veis, Sfeir et al. 1997; Huq, Cross et al. 2005) across multiple
species. This consensus sequence is found to be phosphorylated in small integrin-binding
ligand N-linked glycoprotein (SIBLING) family proteins such as bone sialoprotein, dentin
and osteopontin. The phosphorylated serines in these bone and dentine extracellular matrix
(ECM) proteins have been hypothesized to play an important part in the controlling
interaction of the ECM with hydroxyapatite and mediating mineralization of these tissues
(Narayanan, Ramachandran et al. 2003; Qin, Baba et al. 2004; Toyosawa, Kanatani et al.
2004; Gordon, Tye et al. 2007). Osteopontin (OPN) is another secreted phosphoprotein
found in bone. Phosphorylated residues of osteopontin have also been shown to play a role
in binding calcium mineral (Gericke, Qin et al. 2005).
The work of Behnam, et al. has shown that Spp24 possesses osteoinductive
qualities based on the ability of the TβRII homology domain to interact with BMPs
(Behnam, Phillips et al. 2005). The ability of Spp24’s TβRII domain to enhance the effects
of BMPs in addition to the putative ability of the phosphoserine residues to modulate
mineralization suggest that Spp24 may be an important bone matrix protein in regulating
bone mineralization.
This study details our finding of the up-regulation of Spp24 in the kidney under
low calcium conditions in the rat. Serum and extracellular calcium is an important
regulator of neuromuscular function and skeletal mineralization. The increased synthesis of
renal Spp24 during hypocalcemic conditions may relate to a regulatory mechanism for
controlling extracellular calcium. The absolutely conserved SSEE region within the Spp24
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homology domain of multiple vertebrate species predicts that Spp24 can adhere to
hydroxyapatite and affect an aspect of mineralization.

Materials and Methods
Animals
Hypocalcemic (LC), hypercalcemic (HC), and normal calcium (NC) groups of rats
were generated by following the diet regime of Beckman and DeLuca (Beckman and
DeLuca 2002). Briefly, rats were fed either low calcium or normal calcium diets. To
generate the LC group, animals on the low calcium diet were supplemented with vitamin
D. The HC group was created by feeding animals the normal calcium diet and
administering two injections of 1,25-dihydroxyvitamin D3 [1,25-(OH2)D3] at 16 hrs and at
4 hrs prior to sacrifice. The NC group was fed the normal calcium diet without additional
supplements.
Cell Culture
All cells were kept at 37˚C in a humidified atmosphere of 5% CO2. MG-63 and
SAOS-2 cells were maintained in DMEM:F12 with 10% and 15% FBS, respectively.
Kidney Cells, mouse proximal (MPCT) and distal (DKC-8) tubule epithelial cells were
maintained in DMEM with 10% FBS and 1% penicillin/streptomycin.
Isolation of RNA
Total RNA was isolated from tissues and cells using the Trizol reagent (Invitrogen,
Carlsbad, CA) as described in our previous work (Bajwa, Horst et al. 2005). The resulting
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RNA pellet was re-dissolved in RNase-free water. DNA was removed using a
MessageClean Kit (GenHunter Inc., Nashville, TN) as per the manufacturer’s instructions.
Quantitative RT-PCR
Speific TaqMan® probes were generated to the rat Spp24 and 18s rRNA genes.
Real-time RT-PCR (TaqMan) was performed in a PE Biosystems Model 7700 instrument
at the VCU Nucleic Acids Research Core facility (NARF). Primers were designed using
Primer Express software (PE Biosystems, Foster City, CA) from gene sequences obtained
through GenBank. Gene transcript levels were normalized to 18s rRNA.
Cell and Tissue Distribution Western Blots
For the determination of Spp24 protein regulation, monolayers of cells were grown
in 60mm culture dishes up to 80-90% confluent. Cells were washed with ice cold PBS and
then lysed in MPER lysis buffer (Pierce, Rockford, IL) containing 10 μl/ml of Protease
Inhibitor Cocktail (Pierce). Cell lysates were centrifuged at 14,000g to separate cell protein
from cell debris. The soluble protein content was measured by a Bradford assay (Bio-Rad
Inc, Hercules, CA) and frozen at -70°C. After thawing, the cell lysates were combined with
an equal volume of Laemmli sample buffer (Bio-Rad) heated at 95°C, and separated using
a 10% SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred
electrophoretically to nitrocellulose membranes (Bio-Rad). After transfer, the membranes
were blocked with 5% instant nonfat milk in TBST (20 mM Tris-HCl, 137 mM NaCl, and
0.05% Tween 20) pH 8.0 for 1 hr at room temperature.
Spp24 was detected in mouse and human cell extracts by immunoblotting using an
overnight incubation with 1:1,000 dilution of rabbit polyclonal antiserum specific for
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bovine Spp24 (provided by Dr. Samuel Murray). The blots were incubated in Odyssey
blocking buffer (LI-COR Biosciences, Lincoln, NE) overnight at 4ºC. Blots were washed
4x for 10 minutes each in TBST. Blots were then incubated in solution containing Odyssey
anti-mouse IgG secondary antibody Alexa Fluor-IR800 nm (LI-COR) diluted 1:5000 in
Odyssey blocking buffer for 1 hr and 30 minutes. Blots were finally washed 4x in TBST
and read by the Odyssey Infrared Imaging System (LI-COR).
A membrane representing a human multiple tissue protein blot was obtained from
EMD Biosciences (Calbiochem, San Diego, CA). According to the manufacturer, the
proteins on this blot were isolated from various tissues by preparing tissue homogenates in
the presence of protease inhibitors. Proteins samples (75 μg) from each tissue were
solubilized in SDS-lysis buffer and electrophoresed in a 4-20% SDS-polyacrylamide
gradient gel, followed by electroblotting on PVDF membrane. This membrane was
washed, blocked and then hybridized with a rabbit anti-human Spp24 polyclonal antibody
at a dilution of 1:500. The membrane was washed with TBS containing 0.05% Tween-20
(TBST) and then a fluorescent-conjugated (800nm) secondary antibody was added to the
membrane at a dilution of 1:10,000. Following wash steps, the blot was visualized using an
Odyssey Infrared imaging system (LI-COR). Alpha-tubulin was used as a housekeeping
protein control.
Differential Display RT-PCR
Differential Display RT-PCR (DD) was performed using the RNAspectra kit
(GenHunter), containing three one-base-anchored oligo-dT primers to subdivide the
mRNA population, except they were labeled with 5‘-fluorescein. The use of three one-
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base-anchored primers reduced the redundancy and potential under-representation of the
sub-population of mRNAs encountered by using either eight arbitrary 13mers or three
degenerate two-base-anchored oligo-dT primers. With built-in restriction sites at the 5'
ends of both anchored and arbitrary primers, the longer primer pairs produce highly
selective and reproducible cDNA patterns. To promote high-efficiency reactions,
amplicons were selected in the 50-150 base pair range.
Briefly, samples were run in duplicate to reduce the number of false positives as a
result of high signal to noise ratio often associated with the DD technique. An aliquot of
200ng of total RNA was mixed with an anchor primer (anchor primers: 5’AAGCTTTTTTTTTTTG, 5’-AAGCTTTTTTTTTTTA, 5’-AAGCTTTTTTTTTTTC) and
heated to 65°C for 5 minutes. The sample was transferred to a thermocycler and
maintained at 37°C. Reverse transcriptase was added after 10 minutes and the reactions
were incubated at 37°C for an hour. The generated cDNAs were then used in PCR
reactions. The eight arbitrary primers (arbitrary primers: 5’-AAGCTTGATTGCC,
AAGCTTCGACTGT, AAGCTTTGGTCAG, AAGCTTCTCAACG,
AAGCTTAGTAGGC, AAGCTTGCACCAT, AAGCTTAACGAGG,
AAGCTTTTACCGC) were used in combination with each of the anchor primers. PCR
cycling was performed and the cycle conditions were: 40 cycles of 94°C for 30 seconds,
40°C for 2 minutes, and 72°C for 1 minute.
A 6% Accugel polyaccrylamide gel (National Diagnostics USA, Atlanta, GA) was
loaded and run for approximately 45 minutes at 60 watts. Banding patterns were analyzed
using a Typhoon AutoImager (Molecular Dynamics Inc., Sunnyvale, CA). Differentially
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regulated bands were isolated from the gel and reamplified using the same combination of
initial primers. The PCR fragments were T-A cloned into pGEM T-easy vector (Promega
Corp., Madison, WI), isolated and sequenced. NCBI blast searches were used to analyze
the obtained sequences.
Histology
Rat kidneys were frozen in OCT embedding medium and sectioned. Confocal
immunofluorescence was performed as previously described (Ramage, Urban et al. 2007)
using the anti-Spp24 antibody and corresponding fluorescent-conjugated secondary
antibody. H&E staining was performed on rat kidneys embedded in paraffin at the VCU
Medical Center Pathology lab.
Oligonucleotide Microarray
Microarray was performed on the same RNA samples as were used in the DD
experiment. LC and HC RNA samples were exposed to the Affymetrix Inc. (Santa Clara,
CA), Rat Genome U34A GeneChip® Set, which probed for 7,000 known rat gene
sequences plus 1,000 EST gene cluster sequences. The U34A GeneChips were hybridized
in the presence of fluorescently labeled RNA from each treatment. The GeneChips were
read and analyzed using an Affymetrix GeneChip Reader at the VCU Nucleic Acids
Research facility.
Hydroxyapatite Binding
Media from cells transduced with a CMV promoter controlled Spp24 viral
construct was collected after 6 days. 10 mls of media was placed onto a hydroxyapatite
column and allowed to enter the column by gravity flow using a modified version of the
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protocol of Wecksler and Norman (Wecksler and Norman 1979). The media flowed
through the column and was collected. The column was washed until the A280 of the wash
coming off the column dropped to zero. The bound protein was eluted and collected by
running 6M urea through the column. 10ul aliquots of the media, flow through, and eluate
fractions were saved for Western blotting using an anti-Spp24 antibody as described
above.
Statistical Analysis
Where it applies, results are expressed as the mean ± SE. Significance was
determined by analysis with an unpaired student’s t-test for two-group comparison; p<0.05
were considered significant.

Results
Expression of Spp24 in Tissues and Cell Models
Spp24 gene expression had previously been demonstrated in bovine cortical bone
and liver tissues, but no expression studies of Spp24 have been done in smaller lab
animals. Using the annotated rat Spp24 cDNA sequence, we designed a TaqMan probe
with the Applied Biosystems Primer Express v2.0 software package. Multiple tissues were
harvested from three individual rats, which included; heart, kidney, spleen, stomach, bone
smooth muscle, lung, thymus, small intestine, liver testes and the thyroparathyroid unit. In
the case of bone tissue, we used whole femur, and we followed up this work by also
analyzing epiphyseal ends of the bone and the central diaphyses of each bone. In the
multiple tissue analysis, Spp24 gene expression was only detected in the liver, and
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surprisingly, the kidney (figure 11A). No gene expression of Spp24 was detected in whole
bone (figure 11A), femur ends or midshafts (data not shown). The relative gene expression
of Spp24 from kidney was 1/3 the amount compared to liver (figure 11B). The lower limit
of detection was 80 pg of RNA. It is possible that a low Spp24 gene expression level in
bone tissue was undetectable by this measurement technique.
Given the small number of tissues that express Spp24 mRNA and the fact that
Spp24 is a secreted protein, it is reasonable to predict that the protein localization is more
widespread than its gene expression. This was tested with a multi-tissue blot of human
protein source using a polyclonal anti-bovine Spp24 antibody that can cross-react with
human Spp24 (figure 11C). Detection of Spp24 was nearly ubiquitous in all tissues and
was observed as multiple size bands that were predominantly 55 kDa for most tissues.
Brain tissue had a predominant protein band at approximately 45 kDa, while kidney had
weak detection of a band at 55 kDa and a band strongly detected at 90 kDa. Various kidney
and bone cell models also were utilized for Western blot analysis of Spp24 (figure 11D).
Cellular protein was extracted in two ways. First, lysis buffer was added directly to the
culture well following removal of the medium. This procedure allows for the inclusion of
adhered extracellular matrix proteins with cellular protein content. In the second
procedure, cells were lifted from the well by trypsin, washed with PBS and pelleted to
remove the medium. Then the pellets were lysed for protein extraction. This second
procedure was done to enrich the protein fraction with cellular protein content as opposed
to extracellular protein content. Protein from both procedures was used in Western blots.
Use of 30μg protein from the whole well lysis (first panel of figure 11D) resulted in
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detection of 45 kDa sized bands in murine kidney epithelial cell models, MPCT and DKC8. A similar size band was also detected in human MG-63 osteoblast-like cells whereas in
human SaOS2 osteosarcoma cells the detected band size was 55 kDa. No band was
observed in the lane representing the pluripotent murine C2C12 myoblast cells. These
myoblast cells can convert to osteoblasts under the correct conditions (Katagiri,
Yamaguchi et al. 1994). In contrast, Western blot detection of Spp24 in MG-63 and C2C12
revealed a 24 kDa protein band when the trypsin lysis procedure was used instead of whole
well lysis (second panel of figure 11D). This demonstrates that MG-63 and C2C12 cells
make at least a small amount of unprocessed Spp24. Presumably, secretion results in
higher molecular weight moieties of Spp24.
Regulation of Spp24 in the Rat Kidney
Figure 12A depicts the three main protein components of the fetuin mineral
complex, which include fetuin, matrix-gla-protein and Spp24 (Price, Caputo et al. 2002).
Similar to fetuin, Spp24 contains a cystatin homology domain at its N-terminal side. Fetuin
contains two such domains. Q-PCR of RNA isolated from rat kidneys under normal
calcium (NC) and low calcium (LC) showed the up-regulation of Spp24 transcripts under
LC (figure 12B). The RNA isolated from the kidney cortex of LC (hypocalcemic) and HC
(hypercalcemic) rats was tested for differentially expressed genes involved in the
regulation of calcium homeostasis by differential display (DD) RT-PCR (figure 12C). The
DNA fragments correlating to several negatively and positively regulated mRNA
transcripts were recovered, amplified, and sequenced. The band differentially up-regulated
under LC conditions denoted by the arrow in figure 12C corresponds to Spp24. This
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fragment yielded a partial sequence of Spp24 exactly matching 167 bases at the C-terminus
when compared to the annotated rat Spp24 sequence previously published in GenBank.
RNA from rat kidneys was also subjected to cDNA oligonucleotide microarray to
identify differentially regulated genes in the LC versus the HC. Microarray showed a 5.6fold increase in Spp24 gene expression in the LC group (figure 12D) as compared to the
HC group. In contrast to Spp24, OPN was down-regulated by hypocalcemia in the rat
kidney (figure 12D). In our model several other 1,25(OH)2D3 dependent genes were also
repressed as expected by the hypocalcemic condition in the LC group such as 24hydroxylase, Vitamin D receptor, calbindin, and Ca-ATPase. Therefore, an increase of
Spp24 in the LC condition indicates a lack of regulation by 1,25(OH)2D3 on Spp24 gene
expression in the kidney.
cDNA Sequencing and Protein Structure of the Rat for Spp24
Using RNA isolated from rat liver we cloned out the rat cDNA for Spp24 using
primers to the annotated sequence. The cDNA was sequenced revealing three additional
nucleotides (figure 13A & C) not in the published sequence in GenBank. The additional
nucleotides corresponded to an Arginine in the c-terminal portion of the protein (figure
13B).
Interspecies Post-Translational Modification Mapping of Spp24
Figure 14 depicts rat and mouse species of Spp24 both contain consensus sites for
N-glycosylation just proximal to their SSEE domains. Most phosphorylation domains
among all species analyzed (rat, bovine, human and mouse) appear to be via casein kinase
II, followed by protein kinase C. Human and bovine Spp24 additionally have consensus
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sites for phosphorylation by protein kinase A. Finally, the bovine Spp24 contains one site
for possible tyrosine kinase phosphorylation, and both bovine and mouse forms of Spp24
have consensus myristylation sites in their C-terminal domains.
Localization of Spp24 in the Kidney
Transverse sections of the rat kidney illustrates cortex and medulla areas (figure 15
A and D). Spp24 was detected only in the epithelial cells of the convoluted tubules of the
cortex layer (figure 15 D). Staining was also absent in the collecting ducts (figure 15 E)
and in the glomeruli of cortex sections (figure 15 F).
Hydroxyapatite Binding
Western blot of conditioned media (lane 2), column flow through (lane 3), and
eluate fractions (lanes 3-5) is shown in figure 16. The large amount of Spp24 seen in the
blot entered the column and a majority bound though some is seen in the flow through
(perhaps exceeding the binding capacity of the column). In the eluted material a band
recognized by the anti-Spp24 antibody is seen in early fractions. The large volume of
elution fractions accounts for the considerably smaller band in the elution than that seen in
the conditioned media (lane 2).

Discussion
To date, as few as five papers directly relate to Spp24 and provide only minimal
information about its functional purpose. From these studies Spp24 is described as a thiol
protease inhibitor that affects an aspect of bone remodeling. In the present study, we make
use of the first available antibody raised against bovine Spp24 to examine the tissue
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distribution and protein regulation of Spp24 in several species. The antibody cross-reacts
well with human, rat and mouse forms of Spp24. We also document that renal tissue along
with liver are the predominant sites of Spp24 gene expression, but low amounts of protein
were detected in renal and bone cell models. Intact 24kDa protein can be detected in
myoblast precursors (C2C12 cells) and osteoblasts (MG-63 cells) if the cells are harvested
free of the extracellular matrix component. Secreted Spp24 undergoes post-translational
processing and is detected as higher molecular weight products in bone and kidney cell
models and in a host of tissues. The predominant sizes of Spp24 protein, examined in
mouse and human sample were 45-55kDa. One exception was forms of 55 and 90kDa in
human kidney. The stage of differentiation may also be a factor since we observed a 45kDa
protein in terminally differentiated MG-63 osteoblast like cells and a 55kDa protein in less
differentiated SaOS-2 osteosarcoma cells.
There is extensive tissue distribution of Spp24 in most if not all peripheral tissues.
Based on this finding, we speculate that Spp24 has a broader role in vivo than previously
understood. Spp24 associates with fetuin, matrix Gla protein (MGP) and osteopontin
(OPN) in serum and is thought to participate in regulation of calcium homeostasis along
with these proteins. Targeted mutation of either fetuin, MGP or OPN leads to
complications involving heterotopic calcification of soft tissue organs (Jono, Ikari et al.
2002; Schafer, Heiss et al. 2003; Jono, Ikari et al. 2004; Speer, Chien et al. 2005;
Westenfeld, Schafer et al. 2007). However, Spp24 appears to be involved in processes that
positively regulate bone ossification by cooperating with BMPs. We tested this concept by
examining the regulation of Spp24 in kidney tissue exposed to extremes in blood calcium
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concentration. Since OPN is vitamin D dependent for its expression and undergoes downregulation during hypocalcemic conditions we reasoned that Spp24 would follow a similar
pattern of expression. In contrast, gene expression of the two related phosphoproteins were
oppositely regulated with Spp24 being markedly increased in hypocalcemia. We
additionally found Spp24 expression to be localized to the tubules of the kidney cortex and
not in the medulla.
Isolation of RNA from several rat tissues showed Spp24 expression mainly in the
liver and kidney. The metabolic tissues are important producers of proteins that are
released into the serum. Spp24 was not seen in bone however expression in bone has been
previously reported in bovine tissue studies (Hu, Coulson et al. 1995). Although we did not
see it in the rat, we saw human osteoblast cells in culture showed expression via Western
blot. Accumulation of Spp24 protein in bone (Hu, Coulson et al. 1995), regardless of
expression levels, is an important factor in bone development as reported by others
(Behnam, Phillips et al. 2005). Western blot of human tissue using an anti-human Spp24
antibody shows Spp24 is present in a myriad of tissues with a variety of molecular
weights. It seems clear that there are numerous post-translational modifications that result
in the variable sizes detected in the immunoblot.
We have established that there is an additional previously unreported amino acid
present in the rat Spp24 sequence. The importance of the additional arginine, if any, is
unknown at this time. It is worth noting that the difference in published sequence may be
due to the use of Sprague-Dawley rats whereas the GenBank sequence is published from
Norway rats.
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Post-translational modifications of extracellular matrix proteins can play important
roles in the proteins’ function. We suspect the multiple sizes of Spp24 seen in our Western
blots results from post-translational modification. SIBLING family proteins, known to
bind mineral in calcified tissue, are notably post-translationally modified and are related to
Spp24 by the presence of a SSEE consensus sequence. Similar to SIBLING proteins’
interactions with mineral we found that Spp24 bound to hydroxyapatite. Binding is often
associated with anionic residues perhaps relating a modification such as phosphorylation to
the mineral binding abilites of Spp24 and suggesting a role of Spp24 in matrix calcification
(Veis, Sfeir et al. 1997; Huq, Cross et al. 2005).
This study provides evidence for multiple molecular weight forms of Spp24
(principally 45-55kDa) that were detected in all tissues examined including liver, brain,
lung, kidney, spleen, reproductive organs, heart and pancreas. The source gene expression
of Spp24 was confirmed to be predominantly from the liver, but at least in rats, kidney is
also a major organ for Spp24 expression and the level of expression increases in during
hypocalcemia. The relationship of extracellular Spp24 to bone was reemphasized by the
minimal detection of Spp24 protein in several bone, as well as kidney, cell models and the
ability of Spp24 to bind hydroxyapatite. In conclusion, Spp24 is a multiply phosphorylated
circulating molecule with potentially wide ranging effects on calcium homeostasis.
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Figure 11. Tissue Distribution of Spp24
Q-PCR of rat liver RNA shows the tissues expression Spp24 (A). Greater expression levels
were seen in the liver (B). A Western blot of human tissue protein showed Spp24 was
present in numerous tissues and migrated to several different sizes (C). Western blots of
immortalized cell lines protein extracts showed the presence of Spp24 in kidney epithelial
cells, bone cells and myoblasts (D). The protein extracted from immortalized cells resulted
in different size Spp24 bands based on extraction method; lysis after trypsin treatment of
cells resulted in a sample enriched in intracellular, not extracellular, protein and the
subsequent protein was 24 kDa. rSpp24 in figure D is a recombinant Spp24 protein used
as a positive control.
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Figure 12. Regulation of Spp24 Expression by Serum Calcium Levels
(A) Homology of Spp24 to other bone-related secreted phosphoproteins is depicted
showing the presence of cystatin domains in Spp24 and osteopontin (OPN). Phosphoserine
residues in Spp24 may interact with calcium while MGP interacts with calcium via Gla
domains. (B) Q-PCR of RNA from rat cortical kidney shows Spp24 is up-regulated by low
serum calcium (LC) conditions compared to normal serum calcium (NC) levels. (C) A gel
of differential display PCR from cortical kidney shows the differentially regulated band
(arrow) corresponding to Spp24 under low calcium conditions (LC) as compared to high
serum calcium (HC). (D) An inverse regulation of Spp24 and OPN under low calcium
conditions was found in microarray studies.
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Figure 13. Sequence of Rat Spp24
A cDNA from Rat liver RNA was generated by reverse transcription PCR and sequenced.
The sequence showed the presence of an additional amino acid in the sequence that was
not seen in the annotated sequence available from GenBank. Fig A is our complete cDNA
sequence with the nucleotides encoding the additional amino acid in the box. Fig B shows
the corresponding amino acid sequence with the additional amino acid indicated by an
arrow. Fig C shows the DNA sequence chromatograph with the additional nucleotides
underlined.
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Figure 14. Post-Translational Modification Sites of Spp24
Post-translational modification sites of the rat, bovine, human and mouse Spp24 were
determined using FindMod and GlycoMod software available on ExPASy.com.
Glycosylation, PKC-dependetn phosphorylation, PKA-dependent phosphorylation, casein
kinase-II phosphorylation, and myristylation sites are all shown with the corresponding
amino acid numbers of the computed sites.
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Figure 15. Localization of Spp24 in the Kidney
Panels A, B and C show H&E staining of rat kidneys. Panels C, D and E show confocal
imaging of sections stained with an anti-Spp24 antibody and an alexaFluor-488 secondary
antibody taken at 10x zoom. Spp24 is present in the tubules of the kidney cortex though
clearly absent from glomeruli (F). Spp24 was not seen in the medulla (lower unstained area
of D)
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Figure 16. Hydroxyapatite Binding of Spp24
Media from Spp24 transduced cells was placed onto a hydroxyapatite column. Aliquots of
media, flow-through and eluted fractions were tested by immunoblot. The eluted fractions
showed the presence of Spp24 as detected by the anti-Spp24 antibody. Molecular weight
standards and corresponding weights are shown on the left.
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CHAPTER 3
Secreted Phosphoprotein-24 (Spp24) Promotes Osteoblastogenesis but
Requires BMP Ligand to Activate Runx2 and Osterix Transcription

Abstract
Spp24 is a secreted phosphoprotein shown to accumulate in bone that displays
homology to both cystatin C and TGF-β receptor type-II. Spp24, based on several physical
properties and on in vivo implantation studies, has been suggested to be the original bone
morphogenetic protein which Urist described but never fully isolated. We undertook a
study to examine the role Spp24 plays in the differentiation and function of osteoblasts by
transducing primary human mesenchymal stem cells with adenovirus constructs expressing
Spp24 and LacZ. The results showed 1835 of the 20,000 genes tested were regulated
greater than two-fold. The expression of Spp24, though not resulting in expression of key
osteoblast genes such as Runx2 or OSX did favor an osteoblast phenotype as did notable
morphological changes and the presence of nodule formation. Spp24 appears to alter
mesenchymal character by preventing numerous differentiation paths while it alters
signaling pathways in a manner that primes the cells to react to stimuli that drive
95
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differentiation. We examined how Spp24 affects BMP signaling by running parallel
experiments that were supplemented by treatment with BMPs over the course of the 15
days. This allowed examination of how Spp24 effects are altered by osteoinductive signals
but also how BMP changes cells over longer periods than typically examined in the
literature.

Introduction
Microarray has proven to be an invaluable tool in the study of osteoblast
differentiation and the accompanying cellular changes of gene expression. Typically most
studies utilize a relatively undifferentiated population of cells and provide the activating
stimulus to initiate an osteoblast differentiation program with the recovered data
illuminating the mechanism by which the stimulus acts (Huang, Yang et al. 2007). The
studies have not only provided insightful information about how various stimuli act but
also the behavior of mesenchymal stem cells (MSCs) (Marie and Fromigue 2006). MSCs
have generated a lot of interest as they are easily isolated through bone marrow aspirates
and have great potential with studies showing differentiation of MSCs into osteoblasts
(Haynesworth, Goshima et al. 1992; Bruder, Jaiswal et al. 1997), adipocytes (Pittenger and
Martin 2004), myocytes (Xu, Zhang et al. 2004), neurons and astrocytes (Sanchez-Ramos,
Song et al. 2000; Hofstetter, Schwarz et al. 2002). Most of these studies in focus on early
changes in MSC character as these are the initial steps in the determination of an
osteoblastic fate.
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Studies of osteoblast differentiation have implicated a large number of genes
involved in the transition of cells to osteoblasts. Many studies have examined the changes
that occur during bone morphogenetic protein (BMPs) induced differentiation
(Korchynskyi, Dechering et al. 2003). Studies examining osteoblast differentiation in
undifferentiated cells have shown multiple signaling pathways are involved in this
complex process, indicating a complex signaling network with signaling crosstalk between
Notch, Wnt and BMP pathways likely playing an important role (Canalis, Deregowski et
al. 2005). Similarly, a large number of transcription factors have been shown to play
important roles in altering the transcriptional activity of differentiating cells. Of principal
importance are the transcription factors RUNX2 and OSX that are known to be essential to
osteoblastogenesis (Komori, Yagi et al. 1997; Nakashima, Zhou et al. 2002).
Many signaling pathways have been implicated as regulators of osteoblast
differentiation including Wnt signaling, hepatocyte growth factor (HGF), fibroblast growth
factors (FGFs), and Notch. Wnt’s are critical to bone development as illustrated by the
absence of bone in wnt conditional knockout mice; instead the animals developed only
cartilaginous skeletons with osteoblasts that were not fully differentiated (Hu, Hilton et al.
2005). Canonical Wnt signaling is activated by the binding of Wnts to a heterodimeric
receptor complex composed of a G-protein coupled receptor, Frizzled, and low-density
lipoprotein receptor related protein-5 or -6 (LRP5 or LRP6). Conflicting reports on the role
of HGF have recently appeared in the literature. HGF has been shown to enhance
osteoblastogenesis when adsorbed to hydroxyapatite surfaces (Zambonin, Camerino et al.
2000; Hossain, Irwin et al. 2005). Recently, HGF has also been shown to negatively affect

98
BMP signaling in osteoblast differentiation possibly through the inhibition of receptoractivated SMAD nuclear translocation (Standal, Abildgaard et al. 2007). The discrepancy
between these reports is not fully understood however some of the difference is suggested
to relate to the enhanced self renewal of MSC under transient treatment in some studies
while longer studies with prolonged exposure are more affected by the inhibition of BMP
signaling. Fibroblast growth factor 18 (FGF18) is an important factor in bone development
as it enhances osteoblast differentiation and animals lacking FGF18 experience delayed
bone development (Liu, Xu et al. 2002; Ohbayashi, Shibayama et al. 2002; Liu, Lavine et
al. 2007). Notch signaling is another important pathway involved in osteoblast
development that plays
Secreted phosphoprotein-2 (Spp24) is a secreted protein produced primarily in the
liver and kidney that accumulates in the bone matrix (Sen, Walker et al. 1987; Hu, Coulson
et al. 1995). The sequence of Spp24 reveals a cystatin homology domain in the N-terminal
portion of the molecule that overlaps with a TGF-β receptor II homology (TβRII) domain
(Hu, Coulson et al. 1995; Bennett, Khorram Khorshid et al. 2004). The C-terminal half
contains a Spp24 signature domain conserved in over 20 species of vertebrates and the
cartilaginous dogfish. Within the Spp24 domain is a SSEE sequence that is a conserved
casein kinase recognition motif (Veis, Sfeir et al. 1997) and is also seen in SIBLING
family proteins that play important roles in promoting matrix mineralization in the
calcification of osseous tissues like bone and teeth (Wu and Veis 1990; Qin, Baba et al.
2004; Huq, Cross et al. 2005). Previous work in this lab has shown up-regulation of Spp24
in a study of the regulation of genes in the kidney under hypocalcemic conditions (Bajwa,

99
Horst et al. 2005). Recently, Benham, et al. showed that the TβRII domain of Spp24
(called BMP binding peptide or BBP) when recombinantly produced in bacteria and placed
in animal muscle pouches induced ectopic calcification and bone formation alone and coimplantation of BMP-2 with BBP enhanced the native osteoinductive of BMP-2 (Behnam,
Phillips et al. 2005). They contend (Behnam, Phillips et al. 2005; Dalgleish, Francis et al.
2006) that Spp24 is Marshall Urist’s original bone morphogenetic protein/non-collagenous
protein (BMP/NCP) (Urist 1965). The TβRII domain of Spp24 has been implicated in the
regulation of TGFβ family cytokines such as BMPs while the effect of the Spp24 is unclear
but homology suggests it may be important in matrix calcification in vivo.
This study employed adenoviral over-expression of Spp24 as a means to investigate
the long term effects of Spp24 on MSC differentiation to osteoblasts and on BMP-2/7
heterodimer driven differentiation. After transduction we used microarray analysis at 15
days to examine how the Spp24 over-expression changed the expression profile of these
cells. Results showed changes in expression patterns that created a pre-osteoblastic
condition in cells that while not fully committed to osteoblast differentiation had increased
levels of genes associated with osteoblast differentiation and genes that prevented alternate
pathways of mesenchymal cell differentiation.

Materials and Methods
MSC Isolation and Culture
Bone marrow aspirates were obtained from the femur of primary hip revision
patients at the Virginia Commonwealth University/Medical College of Virginia Medical
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Center via an IRB approved protocol. Bone marrow was transported to the VCU
Orthopaedic Research Laboratory and combined with 2x volume of sterile saline and
mixed by pipette. The bone marrow was layered over a Histopaque 1077 (Sigma) and
centrifuged at 513g for 30 min at 4°C in a swinging bucket rotor with no brake. The layer
in the gradient containing the mononuclear cells was collected by pipette and plated in
plastic flasks for 48 hrs in DMEM Hi-glucose media containing 10% FBS and 1%
penicillin/streptomycin. After 48 hrs the media was changed to remove non-adherent cells
and fresh media with the addition of basic FGF at 2ng/ml (expansion media) was added.
Cells were passaged three times before use in the following experiments.
For the generation of osteoblasts MSCs were cultured either in expansion media (as
described above) or media containing 10 mM β-glycerol phosphate, 0.2 mM Ascorbic acid,
and 10-8 M Dexamethasone (osteogenic media) for 14 days. Additional experiments were
performed where Dexamethasone was replaced with 10ng/ml of BMP-2/7 heterodimer.
Adenoviral Transduction
Mouse Spp24 cDNA and LacZ cDNA were cloned into CMV promoter controlled
adenoviral constructs. The adenoviral constructs were used to transduce MSCs to a
multiplicity of infection (MOI) of 100 viral particles per cell. Experimental groups
examined Spp24 versus LacZ transduction as well as groups where both Spp24 and LacZ
transduction was supplemented with 10ng/ml of BMP 2/7 heterodimer added with each
change of media every 3 days.
RNA Isolation
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RNA from virally transduced MSCs was collected using the TriZOL (invitrogen).
After isolation contaminating DNA was removed from RNA samples using a 30 minute
treatment with DNAse I at 37°C. RNA was stored in RNAse free DEPC-treated water.
Microarray
RNA was hybridized to Affymetrix human U133A GeneChips for microarray
analysis at the VCU Nucleic Acid Core Facility. Gene profiles were further analyzed using
the Affymetrix GCOS v1.4 software to identify biological processes, molecular function
and cellular component effects of treatments.

Results
Spp24 in Osteoblasts
MSCs were cultured 14 days supplemented with β-glycerol phosphate, ascorbic
acid, and either BMP-2/7 or Dexamethasone to induce osteoblast differentiation (as seen
by alizarin red staining in figure 17 A). These cells showed the presence of a smaller ~18
kDa size band, as detected by Western blot (figure 17 B) with an anti-Spp24 antibody, in
the osteogenic media cultured cells while control cells treated with expansion media for the
14 days did not show a 18 kDa size band corresponding to Spp24 .
Morphology and Histology
Alizarin Red staining was used to examine the presence of calcium deposits as a
measure of matrix mineralization (figure 18 A). The Spp24-transduced group showed weak
Alizarin red staining that was more than that seen with the LacZ control transduced group.
Both of the virally transduced groups that were treated with BMP 2/7 heterodmer
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displayed strong alizarin red staining after 15 days however there was no distinguishable
differences between the two. Alkaline phosphatase staining (figure 18 A), a marker of
bone cell activity, was more intense when cells were transduced with an adenovirus
containing Spp24 instead of LacZ, both between cells treated and untreated with BMP. In
both alizarin red staining and alkaline phosphatase staining it appeared that Spp2
transduction without BMP treatment and LacZ transduction with BMP treatment showed
comparable staining and Spp24 adenovirus combined with BMP treatment showed a
greater intensity of staining.Cells transduced with control LacZ virus displayed no distinct
morphological changes over the course of the experiments. They remained in a long
tubular shape and grew to confluence in evenly distributed and parallel aligned mats of
cells. Spp24 transduced cells exhibited distinguishable changes in cell morphology. Cells
were observed to undergo significant rounding over the approximately two week time
course (figure 18 B).
Cells coalesced and nodule formation was observed within the population of cells
(figure 18 B&C). In cells treated with viral transduction and supplemented with BMP 2/7
heterodimer the cells, both Spp24 and LacZ transduced, showed the presence of osteoblast
characteristics with nodule formation and osteoblast morphology. Nodule formation was
comparable between BMP and Spp24 however when there BMP-2/7 was added to Spp24
there were more nodules seen than any other treatment.
Microarray
In the experiment examining gene profile expression between Spp24 and LacZ
transduced MSCs 57.2% of the 22,000 genes on the chip were present at detectable levels.
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Of the detected genes 884 were up-regulated by at least 2-fold while 995 were 2-fold or
greater down-regulated. Table 2 and 3 detail the most up- and down-regulated genes in
these experiments. In addition to these there were also patterns of regulation as suggesting
ectopic expression of Spp24 alters multiple aspects of MSC biology. Gene cluster analysis
shows that among the genes classified in molecular functions, Spp24 affected MAP kinase
activity, metal ion binding, cysteine-type endopeptidases, and protein serine/threonine
kinase activity. Interestingly, among the genes clustered as biological properties there were
numerous categories linked to osteoblast activity: osteoblast differentiation (up-regulation
of TAZ; down-regulation of Msx, Runx2, and Osx), positive regulation of BMP signaling
(up-regulation of BMPRII, Tribbles, Id2, and Id3), negative regulation of TGFβ signaling
(down-regulation of Smad2, Smad3, TIEG, and Cerberus), and negative regulation of Wnt
signaling pathway (downregulation of FGF18, Wnt5a, Axin, and APC). Interestingly there
was also some negative regulation of BMP signaling with follistatin and chordin downregulated while HGF antagonist was up-regulated. The Notch signaling pathway also
displayed positive regulation as Notch, Jagged, and Hey2 were up-regulated. Groups of
genes associated with alternate differentiation pathways of MSCs were regulated; genes for
chondrocyte (Sox9, COMP), adipocyte (PPARδ, C/EBPβ, adipsin), and myocyte (myosin,
desmin) differentiation were all down-regulated.
Tables 4 and 5 detail the most highly regulated genes from microarrays that looked
at Spp24 transduction compared to LacZ transduction when both were supplemented with
BMP-2/7 heterodimer. Collagen expression patterns changed as was seen by two highly
regulated genes, COL5a3 and COL4a3, being up- and down-regulated, repectively.
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HOXA11 is another up-regulated gene important in skeletal patterning and mesenchymal
cell differentiation.

Discussion
Spp24 was shown to enhance BMP signaling and had an intrinsic osteogenic
activity in in vivo implantation experiments conducted by Behnam, et al. (Behnam, Phillips
et al. 2005). They found an 18.5 kDa fragment of Spp24 in their isolation of bone proteins
similar to the ~18 kDa size fragment of Spp24 that was seen as the MSCs were exposed to
conditions leading to osteoblast generation. To understand this activity we employed viral
transduction as a method of over-expressing Spp24 in undifferentiated MSCs. Examination
of morphological changes showed that the expression of Spp24 led to the limited formation
of nodules characteristic of in vitro osteoblast cultures (Nefussi, Boy-Lefevre et al. 1985;
Bhargava, Bar-Lev et al. 1988). Similarly cells transduced with Spp24 showed weak
Alizarin red staining compared to the control transduced cells. These preliminary
indications suggest that the over-expression of Spp24 may be pushing the cells to a more
osteogenic phenotype; however it is worth noting that the typical experiments driving
undifferentiated cells towards osteoblasts using BMPs, dexamethasone, or other known
osteogenic molecules result in these changes in a shorter amount of time and this may
indicate Spp24 is not as potent an osteogenic factor as some of the classical inducers of
osteoblastogenesis.
To analyze exactly how Spp24 affects these changes in the MSCs we utilized
microarrays. While the hallmarks of osteoblast differentiation, up-regulation of the
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transcription factor Runx2 and its accompanying downstream transcription factor Osx
were not seen there were significant changes that activate or potentiate pathways that will
do affect osteoblast activity. The down-regulation of Runx2 and Osx shows the cells were
not differentiated to osteoblasts, the down-regulation of significant effectors of alternate
differentiation pathways, notably myocyte, adipocyte and chondrocyte, suggest that Spp24
may prevent these differentiation outcomes. An increase in TAZ demonstrates that Spp24
regulates a key step in initial osteoblast differentiation. TAZ is considered a critical
rheostat that inhibits adipogenesis in MSCs while preserving the self-renewal aspect of the
early osteoblast.
Numerous signaling pathways that have been implicated in osteoblast
differentiation were seen to be regulated by Spp24 over-expression. Noteworthy among the
regulated genes by Spp24 was the increase in Tribbles, a protein that affects cell cycle and
migration control through its ability to target protein for proteasomal degradation. A
Tribbles family member protein, Tribbles-3, was recently shown to interact with BMP
receptor type II’s cytoplasmic tail domain, and upon ligand binding Trb3 is released and
targets Smurfs for proteasomal degradation. The degradation of Smurfs enhances the
stability of Smads and their BMP signaling activity. The up-regulation of Tribbles may
provide a mechanism for the osteoblast-like character of MSCs transduced with Spp24.
The overall picture of Spp24’s effects on MSC suggests a molecule that primes cells for an
osteoblast phenotype despite not leading to fully committed differentiation while at the
same time blocking alternate differentiation schemes.
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Overexpression of Spp24 with BMPs showed a number of similar genes, however
there was a significant change that seemed to result in a more fully committed osteoblast
cell. As seen in the table of highly regulated genes collagen expression patterns changed
with COL1a1 also being up-regulated 2-fold. Additionally several MMPs were upregulated. TGFβ expression decreased 2.4 fold when BMP treatment was combined with
Spp24 transduction.
Spp24 is a secreted molecule that accumulates in the bone matrix and its function
in bone is just beginning to be understood. It is predicted that Spp24 functions both
independently of BMP ligands and in combination with BMPs once converted to a shorter
active peptide. This study presents evidence for an important role of Spp24 in steering
mesenchymal cell differentiation towards an osteoblast lineage. Additionally the
interaction of Spp24 with TGFβ family ligands is an important function of Spp24,
particularly relevant to bone mineralization is the interaction with BMPs. In conclusion,
Spp24 appears to regulate early osteoblast differentiation by up-regulating the
Notch/Jagged signaling pathway and by stimulating the rheostat gene TAZ. The combined
effect of treatment of Spp24 with BMP accelerates BMP-mediated osteoblastogenesis and
matrix mineralization.
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Figure 17. Osteoblast Differentiation is Accompanied by a Conversion of Spp24 to
Spp18
Osteoinductive properties of Spp24 induced by Dex and BMP. MSCs were cultured in
DMEM with 10% FBS, beta glycerophosphate, ascorbic acid and dex (10 -8 M) and
BMP2/7 (10ng/ml) for 15 days. Treatments were renewed every 3 days. Total cell extracts
were used to analyze Spp24 expression. A) Osteoblast phenotype was examined by
alizarin Red staining that showed the mineralization of extracellular matrix B) Western
Blot results revealed that a smaller form of Spp24 was upregulated by both dex and
BMP2/7 treatments. Cells also showed morphological changes during these time period.
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Figure 18. Effect of Spp24 Overexpression on Mineralization and Nodule Formation
Effect of over expression of full length mouse Spp24 in MSC following 15 days
adenoviral transduction. A) MSC cells after third passage were transduced with lacZ and
spp24 adenoviral contrruct. Adenoviral LacZ used as a control transduction to adenoviral
spp24. After transduction MSCs were cultured in DMEM with 10% FBS, beta
glycerophosphate, ascorbic acid and with or without BMP2/7(10ng/ml) for 15 days.
Renewal of media was done every 3 days interval. Results revealed that at day 14 mspp24
expression induced significant osteoblastogenesis assessed by alkaline phosphatase and
alizarin Red staining. B-C) Morphological changes during osteogenesis and average counts
of bone forming nodules per 10X power field. Adenoviral transduction was done either
with LacZ control or Spp24 and both were treated vehicle and 10ng/ml BMP2/7 for 14
days. Medium was changed every 3 days interval. Seven independent fields were selected
to get an average.
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Table 2. Genes Increased by Spp24 Transduction
Genes highly up-regulated by Spp24 transduction compared to LacZ transduction of MSCs
after 15 days.
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Accession No.

Gene

Symbol

NM_007345

Zinc finger protein 236

ZNF236

15.8

NM_005768

Putative protein similar to Drosophila nessy

C3F

10.4

NM_002021

Flavin containing monooxygenase 1

FMO1

10.2

NM_080657

Radical S-adenosyl methionine domain containing 2

RSAD2

9

NM_006887

zinc finger protein 36, C3H type-like 2

ZFP36L2

9

NM_002317

Lysyl oxidase

NM_003242

Transforming growth factor, beta receptor II

Fold Change

LOX

8.8

TGFBR2

8.8

NM_001007097

Neurotrophic tyrosine kinase, receptor, type 2

NTRK2

8.4

NM_001850
NM_001033026

Collagen, type VIII, alpha 1

COL8A1

8.2

Chromosome 19 open reading frame 6

C19orf6

8

D38081

Thromboxane A2 receptor

NM_007368

-

8

RAS p21 protein activator 3

RASA3

8

NM_002872

Ras-related C3 botulinum toxin substrate 2

7.8

NM_004587

Ribosome binding protein 1

RAC2
RRBP1

AF091627

p73-like tumor protein

CUSP

7.6
7.6

7.6

NM_016593

Oxysterol 7alpha-hydroxylase

CYP39A1

U77949

Cdc6-related protein

HsCDC6

7.4

AF074480

CMP-N-acetylneuraminic acid hydroxylase

-

7.4

AF028333

Growth/differentiation factor-11

GDF11

7.2

NM_002983

Small inducible cytokine A3

SCYA3

7

NM_003999

Oncostatin M receptor

OSMR

6.8

NM_002028

Farnesyltransferase, CAAX box, beta

FNTB

6.8

NM_000201

Intercellular adhesion molecule 1

ICAM1

6.8
6.8

D84140

Immunoglobulin light chain V region

maB56

NM_001508

G protein-coupled receptor 39

GPR39

6.6

NM_182487

Olfactomedin-like 2A

OLFML2A

6.4

NM_003728

unc5 C

AF044286

Histone macroH2A1.1

NM_005623
NM_024609
NM_002318

Lysyl oxidase-like 2

UNC5C

6.4

-

6.4

Chemokine (C-C motif) ligand 8

CCL8

6.2

Nestin

NES

6.2

LOXL2

6.2
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Table 3. Genes Decreased by Spp24 Transduction
Genes highly down-regulated by Spp24 transduction compared to LacZ transduction of
MSCs after 15 days.

114

Accession No.

Gene

NM_002825

Pleiotrophin

NM_018518

Minichromosome maintenance complex component 10

NM_014246

Symbol

Fold Change

PTN

-11.8

MCM10

-10.8

Cadherin, EGF LAG seven-pass G-type receptor 1

CELSR1

-10.2

SETMAR

-9.6

TF

-9.2

NM_006515

SET domain and mariner transposase fusion gene

NM_001063

Transferrin

NM_004049

BCL2-related protein A1

NM_002888

Retinoic acid receptor responder 1 (tazarotene induced)

AK021983

cDNA FLJ11921 fis, clone HEMBB1000318

NM_001147

Angiopoietin 2

NM_003862

Fibroblast growth factor 18

BC000527

Ewing sarcoma breakpoint region 1

NM_018700

Zinc-binding protein Rbcc728

NM_004543

Nebulin

NM_001861

Cytochrome c oxidase subunit IV

NM_022780

Required for meiotic nuclear division 5 homolog A

RMND5A

-7

NM_004876

Zinc finger protein 254

ZNF254

-6.6

NM_024115

Hypothetical protein MGC4309

NM_021647

Microfibrillar-associated protein 3-like

X58987

D-1 dopamine receptor.

NM_016619
NM_025054

Placenta-specific 8
Valosin-containing protein (p97)/p47complex-interacting
protein p135

NM_015094

Hypermethylated in cancer 2

M27830

28S ribosomal RNA gene

BCL2A1

-9

RARRES1

-8.8

-

-8.8

ANGPT2

-8.8

FGF18

-7.4

-

-7.4

Rbcc728

-7.2

NEB

-7.2

COX4I1

-7

-

-6.6

MFAP3L

-6.6

-

-6.6

PLAC8
VCIP135

-6.2
-6

HIC2

-6

-

-5.8

NM_004364

CCAATenhancer binding protein alpha

CEBPA

-5.8

NM_025154

unc-84 homolog A

UNC84A

-5.8

NM_014950

Zinc finger and BTB domain containing 1

xu43g07.x1

cDNA FLJ12327 fis, clone MAMMA1002140

ZBTB1

-5.8

-

-5.4

X80821

Ribosomal protein L18a homologue.

-

-5.4

NM_014645

Centrosomal protein 135kDa

CEP135

-5.2

U26662

Neuronal pentraxin II

NPTX2

-5.2

NM_002090

GRO3 oncogene

GRO3

-5.2
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Figure 19. Regulation of Genes by Spp24 Transduction
Shown is the regulation of specific genes as found in our microarray study. Genes are
grouped by similarity of function. TGF-β signaling pathways were decreased; Notch and
Jagged genes regulating differentiation were decreased; Wnt signaling was decreased;
HGF signaling was increased; FGF-18 signaling was decreased; Osteoblast progression
was halted; markers of myeloid fate were decreased; bone remodeling was increased; Early
osteoblast development was seen with Groβ increasing to delay mineralization; and finally
matrix development was increased. These gene regulation patterns show how Spp24 alters
MSC differentiation holding cells in a pre-osteoblast state
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Table 4. Genes Increased by Spp24 + BMP Treatment
Highly up-regulated genes in cells transduced with Spp24 and treated with BMP-2/7
compared to cells transduced with LacZ and treated with BMP-2/7.
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Accession No.

Gene

Symbol

Fold Change

NM_002155

Heat shock 70kD protein 6

HSPA6

19.8

NM_007345

Zinc finger protein 236

NM_0022144

Myodulin protein

M27830

28S ribosomal RNA gene

U88968

Alpha enolase like 1

NM_005733

RAB6 interacting, kinesin-like

NM_005523

Homeo box A11

NM_018492

PDZ-binding kinase

NM_001034
NM_014750

Ribonucleotide reductase M2 polypeptide
discs, large homolog 7

X51757

Heat-shock protein HSP70B

NM_002421
NM_018136

Matrix metalloproteinase 1
Abnormal spindle homolog microcephaly associated

NM_000361

Thrombomodulin

NM_004887

ZFP236

12.8

LOC64102

11

-

10.6

ENO1L1

10.6

RAB6KIFL

10.6

HOXA11

10.2

PBK

10

RRM2
DLG7

10
9.8

HSP70B'

9.8

MMP1

9.6

ASPM

9

THBD
CXCL14

8.6

9

BC003186

chemokine (C-X-C motif) ligand 14
GINS complex subunit 2

-

8.6

NM_001927

Desmin

DES

8.6

NM_003318

TTK protein kinase

TTK

8.2

NM_015719

Collagen, type V, alpha 3

COL5A3

8.2

NM_005397

Podocalyxin-like

PODXL

8.2
8.2

AF274954

PNAS-29

-

D88357

CDC2 delta T

-

7.8

NM_004417

Dual specificity phosphatase 1

DUSP1

7.8

NM_006240

Protein phosphatase, EF hand calcium-binding domain 1
Epidermal Langerhans cell protein LCP1

PPEF1

7.8

AL117508

-

7.6

NM_030945

Complement-c1q tumor necrosis factor-related protein

CTRP3

7.4

M10098

18S rRNA gene

U36189

p311 protein

-

7.2

hP311

7.2
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Table 5. Genes Decreased by Spp24 + BMP Treatment
Genes down-regulated in cells transduced with Spp24 and treated with BMP-2/7 compared
to cells transduced with LacZ and treated with BMP-2/7.
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Accession No.

Gene

NM_002825

Peiotrophin

Symbol

Fold Change

PTN

-13

NM_138618

Rhesus blood group, CcEe antigens

RHCE

-12

NM_005000

NADH dehydrogenase 1 alpha subcomplex, 5

NDUFA5

-10.4

NM_031366

Collagen, type IV, alpha 3

COL4A3

-10

-

-9.6

AK022215

cDNA FLJ12153 fis, clone MAMMA1000458

NM_001508

G-Protein Coupled Receptor 39

GPR39

-9.4

NM_0022049

G-Protein Coupled Receptor 88

GPR88

-8.6

NM_003236

Transforming growth factor, alpha

TGFA

-8.6

NT_005612

Chromosome 3 genomic contig, reference assembly

-

-8

M60333

Human MHC class II HLA-DRA

-

-8

NM_080740

Suppressor of hairy wing homolog 1

SUHW1

-8

NM_002276

Keratin 19

KRT19

-7.8

U47054

Mono-ADP-ribosyltransferase

NM_003810

Tumor necrosis factor superfamily, member 10

NM_004967

Integrin-binding sialoprotein

NM_007360

killer cell lectin-like receptor subfamily K, member 1

NM_004139

Lipopolysaccharide-binding protein

U32500

Type 2 neuropeptide Y receptor

NM_021778

A disintegrin and metalloproteinase domain 28

NM_013314

B cell linker protein

NW_922162

Chromosome 4 genomic contig

NM_020904

Pleckstrin homology domain-containing, family A member 4

NM_003566

Early endosome antigen 1

NM_003619

Protease, serine, 12 (neurotrypsin, motopsin)

U57059

Apo-2 ligand

AL133386

Bone morphogenetic protein 5

NM_002125

Major histocompatibility complex, class II, DR beta 5

NM_000882
NM_016619

htMART

-7.6

TNFSF10

-7.6

IBSP

-7.4

KLRK1

-7.4

LBP

-7.4

-

-7.2

ADAM28

-7.2

SLP65

-7

-

-7

PLEKHA4

-7

EEA1

-6.8

PRSS12

-6.8

-

-6.8

BMP5

-6.6

HLA-DRB5

-6.6

Interleukin 12A

IL12A

-6.6

Placenta-specific 8

PLAC8

-6.6

123

Figure 20. Spp24 Effects on MSCs
Spp24 transduction of MSCs elicited responses that blocked activation of critical
osteoblast transcription factors RUNX2/CBFA1 and OSX. The effect of Spp24 on several
important pathways in MSC differentiation are shown
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CHAPTER 4
Conclusion and Future Directions

Studies in the literature have shown that Spp24 is both a protein that accumulates in
bone and has a major effect on bone formation. We have examined the novel discovery of
Spp24 in the kidney and described its expression in numerous tissues and cell lines.
Additionally, we have investigated the effect of Spp24 on mesenchymal stem cells (MSCs)
and how Spp24 alters BMP signaling on MSCs. These studies have provided great insight
into the role or roles of Spp24 in vivo.
Investigations into the role of low calcium regulating genes in the kidney cortex led
to the discovery that Spp24 is highly up-regulated under low serum calcium conditions.
The previously unreported expression in the kidney cortex was strengthened by evidence
of Spp24 seen in Western blots of kidney epithelial cells as well as in confocal microscopy
showing expression in the kidney tubules. An interesting finding in Western blots of
different cell models of both kidney and bone cells was the presence of higher size forms
of Spp24. Sequence analysis showed there is a likelihood of multiple post-translational
modifications including glycosylation, phosphorylation, and myristylation. There was also
significant amount of protein seen in numerous tissues when a blot of multiple human
125
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tissues was probed with the anti-Spp24 antibody. The presence in multiple tissues is not
entirely surprising considering Spp24 is a secreted molecule that is part of a serum protein
complex, but it does raise the question of what purpose that complex and Spp24 might
serve in some of the distant tissues.
Sequencing of the rat Spp24 from liver RNA showed an additional base not present
in the sequence published in GenBank. Clearly we will need to examine this further and
report the results. The published sequence is for Rattus Norvegicus while we used
Sprague-Dawley rats which could be a reason for the difference and it would be useful too
compare sequences of RNA isolated from both animals. Also it would be necessary to
sequence RNA from more animals to confirm our results. As a final step we need to
express our cDNA in cells in culture before a sequence can be reported.
Spp24 has been found by both Senn, et al. and Behnam, et al. to be osteogenic and
we investigated how Spp24 causes bone formation using microarray. Increased
mineralization of cells cultured in vitro and distinct morphological changes accompanied
the over-expression of Spp24 in MSCs. The unusual finding was the lacking of
commitment of MSCs treated with Spp24 to an osteoblast lineage (no up-regulation of
Runx2 or Osx) but instead there was a general trend to prevent full commitment to any
lineage while instead activating other osteoblast related genes. The findings suggest Spp24
may be a molecule that causes cells to be primed to receive osteogenic signals. Our current
understanding of Spp24’s role in osteoblast differentiation is depicted in Figure 22. This
activity of Spp24 is particularly interesting in a matrix protein that has also been shown to
interact with BMPs. The method(s) of how Spp24 causes these cellular changes is still a
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critical step that must be elucidated. Analysis of the sequence of Spp24 suggests many
possible domains may play a role in this activity. Additional work in our lab has shown a
dual effect of Spp24 on BMP activity; early activity represses BMP signaling while late
potentiates BMP signaling. Accompanying the enhancing activity is the transition from
larger molecular weight forms to a smaller ~18 kDa form.

128

Figure 21. The Role of Spp24 in Osteoblast Development
We believe Spp24 may act to in subtly different ways to promote the transformation of
undifferentiated MSCs to osteoblast precursors where Spp24 holds these non-terminally
differentiated cells. The combination of additional growth factors and the proteolytically
digested 18 kDa form of Spp24 (Spp18) could then promote complete commitment to
terminal osteoblastogenesis.
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Investigating how Spp24 acts seems an area full of potentially exciting future
directions for study. Clearly important are how Spp24 acts differently in its larger or
smaller forms. Similarly, how the conversion to a smaller form occurs is important as well
and may be related to the proteolytic cleavage necessary for the activation of SIBLING
proteins (Qin, Baba et al. 2004). Based on the formation of an ~18.5 kDa form of Spp24
during osteoblast differentiation it seems likely that a protease produced during the
commitment program of MSCs to osteoblasts may be involved in this mechanism.
Numerous MMPs and other proteases are produced that may occupy this role.
We have generated numerous site-directed mutants based on an analysis of a
sequence comparison of Spp24 from numerous species of vertebrates. These mutants will
provide a mechanism to investigate a number of aspects of Spp24 biology. Mutants that
block hypothesized cleavage sites that might be involved in the generation of a smaller,
more osteogenic 18 kDa form could be vital to understanding how the conversion of forms
alters Spp24’s effect on differentiation and signaling. Additionally, mutants were
generated to address how possible phosphorylation sites may alter how Spp24 affects
mineralization in culture. We looked at both sites shown to be possible phosphorylation
sites and the conserved SSEE domain related to SIBLING proteins’ functions. Also, we
will look at how mutating the TGFβ receptor domain and disrupting the structure will
affect Spp24 activity.
One additional avenue for future directions is to employ transgenic animals to
investigate the role of Spp24 in vivo. We are beginning to look at the generation of
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transgenic and knockout animals. The generation of full length and ~18 kDa form
transgenic animals with the genes expressed in bone via a collagen promoter could
demonstrate the differences between the forms and how they affect bone. Knockout
animals will likely exhibit decreased bone formation or mineralization. There may also be
distant effects such as soft tissue calcification based on the function of Spp24 in the fetuin
mineral complex.
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APPENDIX A

Bacterial Protein Expression
A cDNA sequence of human Spp24 was placed in the pQE-60 vector (Qiagen) for
bacterial expression. To incorporate the Spp24 cDNA into the vector an Nco I restriction
site was engineered at the 5’ end of the mature Spp24 (without the native start codon and
the signal peptide) and a BamH I site was engineered just at the 3’ end of the sequence
(except for the stop codon so that the bacterial protein product would contain the 6x His
tag from the vector sequence). The engineered sites allowed incorporation of the cDNA
into the vectors’ existing restriction sites as well as eliminating the signal peptide and
termination codon from the sequence so that the protein would not contain the signal
peptide just like the mature protein following secretion from eukaryotic cells. The removal
of the termination codon allowed the incorporation of a 6x His tag.
To express the protein the M-15[pREP4] strain of E. coli were transformed with the
pQE-60/hSpp24 plasmid. M-15[pREP4] cells contain the pREP4 plasmid which confers
kanamycin resistance as well as containing the Lac repressor (alternatively, another E. coli
strain, SG13009[pREP4], also contains the pREP4 plasmid and can be used as a suitable
expression host). IPTG is used to turn off the lac repressor and allow expression. A single
colony was chosen and grown overnight in LB media containing ampicillin (50 µg/ml).
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The followin day LB media was inoculated with portions of the previous night’s cultures.
The cultures were then grown at 37º C with shaking until they reached an OD600 = 0.6
absorbance units. Once they reached OD600 = 0.6, IPTG was added to turn off the
repressive function of the lac repressor and allow expression of the protein. The bacteria
were then allowed to express the protein for 3 hrs.
Cultures were then pelleted by centrifugation. The pellets were resuspended in
20mM phosphate buffer. Bacteria were lysed in a cell breaker. The lysate was centrifuged
to pellet cell debris and insoluble material. The soluble fraction was saved to be run on a
gel. The pelleted insoluble material was resuspended in 6M urea and the insoluble material
was again pelleted by centrifugation. The proteins remaining in the 6M urea were placed
on a Ni-sepharose column to be separated by affinity chromatography based on the
interaction of the 6x His tag with the Nickel. After the protein had entered the column by
gravity flow, 6M urea was used to wash the column. Washing was performed with
sufficient volume to remove unbound additional protein as seen by a drop in the
absorbance (A280) of column effluent to approximately the same absorbance as for 6M
urea. At this point the protein was removed from the column by putting 6M urea
containing EDTA. Fractions of the eluate were collected and also ran on a gel. The
fractions containing the large bands of protein as evidenced on SDS-PAGE gels were
pooled and dialyzed.
During expression of human recombinant Spp24 we found that the protein was
largely insoluble and this fact often made isolation and utilization of Spp24 difficult. To
demonstrate the protein was expressed and present in the insoluble material bacteria were
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transformed, grown and induced. At the indicated time points a portion was taken, spun
down, the supernatant decanted and the pellet was frozen. When samples had been
collected over the whole time course the pellets were thawed and a sufficient volume of
BugBuster (Novagen) reagent was added to solubilize most proteins. Following addition of
BugBuster the insoluble material was pelletted by centrifugation. No Spp24 was found in
the soluble portion (not shown). To look at the insoluble material laemelli buffer was
added to the pelletted material and samples were boiled for 10 min prior to electrophoresis.
The samples were run, along with a sample from uninduced bacteria as a negative control.
The gel was run and transferred to a nitrocellulose membrane. The membrane was
incubated with an antibody raised against bovine Spp24 protein. An infra-red fluorescent
secondary antibody was used to detect the protein. The blot was scanned using the Li-Cor
Odyssey Imaging System. We found that following induction with IPTG expression of the
protein was only seen in the insoluble portion.
We isolated the protein in large quantities and set about finding a suitable method
to isolate a protein that could be soluble and properly folded. Initially we tried several
buffers but none we able to resolubilize the protein. Based on the acidic isolation of Spp24
from tissues, specifically bone, we tried a citrate buffer at a pH of 2.5 but were still unable
to solubilize Spp24. The proteins were solubilized in the buffer at a pH of 2.5 but the pH
was raised to greater than 6 so that the necessary interactions between the 6xHis tag and
the column could occur and allow binding of the protein to the column. Citrate did not
work as a resolubilization buffer. As urea appeared the only suitable way to achieve
binding of our protein to the column we sought ways to dialyze the eluted protein into
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other solutions and maintain solubility after isolation. Dialysis against phosphate buffer
and water both resulted in protein precipitation. We tried to slowly change the surrounding
solution from 6M urea to a buffered solution by adding dropwise a phosphate buffer
solution (we alternatively added the citrate buffer as well) in sufficient volume to remove
the urea and leave the protein in dialysis in the buffer solution. This did not achieve our
goal either resulting in protein precipitation after the buffer was slowly changed overnight
at 4°C.
While we were able to achieve expression of the human Spp24 protein in bacteria
we were not able to successfully solubilize the protein in any solution other than 6M urea.
As other aspects of this project, namely adenoviral expression began to gain traction we
shifted our focus from recombinant expression in bacteria due to the lack of a suitable
solution to resuspend Spp24. This avenue may be an important method to consider at a
later juncture as colleagues have reported implanting the insoluble material in animals and
achieving ectopic bone formation, however with the systems now in place we are currently
looking to investigate how this molecule acts before continuing with bacterial expression.
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Figure 22. Expression of Spp24 as an Insoluble Protein
Western blot of insoluble material from bacterial expression cultures of Spp24 after isolation
using BugBuster reagent. Notice the lack of a 24 kDa band in the uninduced lane as well as the
recombinant Spp24 provided from a collaborator.
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Figure 23. Expression and Isolation of Recombinant Human Spp24
Spp24 was not soluble in phosphate buffer (lane 4). Spp24, after solubilization in 6M urea and
being loaded onto the column, was seen in eluate fractions #2 -5. Attempts to solubilize the
protein in citric acid were unsuccessful.
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Spp24 was not soluble in phosphate buffer (lane 4). Spp24, after solubilization in 6M urea and
being loaded onto the column, was seen in eluate fractions #2 -5. Attempts to solubilize the
protein in citric acid were unsuccessful.
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APPENDIX B

Site Directed Mutagenesis
A pCDNA3 construct containing mouse Spp24 with a 3x HA C-terminal tag was
used as a template for site-directed mutagenesis reactions. Site-directed mutagenesis was
performed using the Stratagene Quik-change II Site-Directed Mutagenesis kit (Stratagene)
and protocol with minor modificatitons. Briefly, PCR reactions were set up with 125ng
each of forward and reverse mutagenesis primers. 50ng of the pCDNA3 construct was
used as template in a reaction with 2.5 U of PfuUltra HF DNA polymerase. The reaction
conditions were as follows: an initial step of 30 secs at 95° C, followed by repeated cycles
of 95° C for 30 sec, 55° C for 1 min, and 68° for 12 min. The cycles were performed 20
times for single amio acid mutations and 22 for multiple amino acid mutations. A final step
at 68° C was performed for 10 min then Dpn I restriction enzyme (10U) was added to the
reactions and incubated at 37° C for 1 hr to digest the methylated template DNA. The
reactions were transformed into competent bacteria and plated overnight on LB/ampicillin
plates at 37° C. Colonies were selected and plasmid preps made for sequencing using
primers to the CMV promoter and the BGH poly-A sequences of the pCDNA3 construct.
Primers were generated with a Tm ≥ 78°C using the Stratagene QuikChange® Primer Tm
Calculator available online at www.stratagene.com/QPCR/
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tmCalc.aspx. Primers are listed in the accompanying table.
Mutations were chosen based on the material provided by a colleague showing the
presence of highly conserved residues throughout Spp24 in over 20 species.
Particularly we focused on residues known or likely to be phosphorylated including sites
around the casein kinase II phosphorylation recognition motif and residues that may affect
Spp24 structure including the TGFβ receptor type II homology domain. The mutation of
N46 to W based on the discovery of an active, ~18 kDa form. An 18kDa form would likely
be cleaved, from the N-terminus at somewhere around N46 and because N46 is conserved
in all 22 species we chose this residue. We mutated it to a tryptophan in an effort to
prevent any proteolysis at this side by hindering possible proteases’ interaction through the
incorporation of such a bulky residue. We also mutated L54 to alanine in an effort to
completely change the character of this highly conserved amino acid. In examining
possible phosphorylation we mutated S137 and T84. as a control for mutagenesis
experiments we took a serine, S80, not shown to be phosphorylated and mutated it as well.
We mutated two cysteines shown to be involved in two distinct disulfide bond interactions,
C96 and C127. C127 is of particular interest based on Behnam et al.’s results that
linearized BBP did not induce bone formation when implanted in vivo. We last examined
the function of the SSEE domain by mutation S137, S137 and S138 together, S138 and
E139 together, and finally E140.
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Figure 24. Site Directed Mutagenesis
Part A illustrates the sites mutated (denoted with asterisks) on the mouse Spp24. Part B
shows the primers used to generate the site-directed mutated pcDNA clones are listed in
the table. The codons corresponding to the mutated amino acid(s) are highlighted in red.
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